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ABSTRACT
The aim of this study was to study the role of sudden cardiac death (SCD) and 
life-threatening ventricular arrhythmias (VA) in cardiac sarcoidosis (CS) and giant 
cell myocarditis (GCM), and to investigate the clinicopathological relationship 
between these diseases.
CS is the cardiac manifestation of sarcoidosis, a systemic disease of unknown 
etiology. The hallmark of sarcoidosis is the non-caseating granulomatous 
inflammation seen in affected organs. GCM is a rare myocardial inflammatory 
disease characterized by widespread myocardial destruction, eosinophilia, and 
giant cells in the absence of granulomas. Clinically significant VAs are common in 
both CS and GCM and sometimes SCD is their first manifestation. For this study, 
all CS and GCM patients detected both from the national research register and 
from the cause-of-death register from 1998 until the end of 2015 were included. 
Additionally, clinically manifest cases of GCM from 1991 to 1998 were included. 
Hospital charts, autopsy reports, and histological material were reviewed and 
cardiac magnetic resonance imaging (CMRI) studies for a subpopulation of 59 
CS patients were analyzed.
The study included 351 cases of CS and 29 cases of GCM. The detection rate of 
both diseases increased over the study period. Female predominance was seen in 
both CS and GCM. At the time of presentation, the mean age of CS and GCM patients 
was 52 and 57 years, respectively. The spectrum of manifestations was similar in 
both diseases. The most common clinical presentation was atrioventricular block 
in CS and heart failure in GCM. SCD was the first sign of myocardial disease in 
14% of cases in both the CS and GCM cohorts. The role of SCD as the mode of 
death was substantial in both diseases: it accounted for four out of five fatalities 
in CS and nearly half in GCM. 
Over half of the cases originally diagnosed as GCM were converted to CS 
after reevaluation, most commonly due to missed myocardial granulomas 
or misclassification as GCM, despite recognition of cardiac or extra-cardiac 
granulomas. Lifetime symptomatic CS patients with an initial diagnosis of GCM 
had a better five-year transplant-free survival (46%) compared to “true” GCM 
patients (27%), but the groups did not differ with regard to cumulative incidence 
of SCD. 
The 10-year survival in lifetime-diagnosed CS patients was 87%. Several CMRI 
parameters were associated with worse transplant-free survival free of VAs. These 
included higher late gadolinium enhancement extent, lower right ventricular 
ejection fraction and thinning (< 4mm) of the basal interventricular septum. 
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In GCM, the five-year overall and transplant-free survival rates were 67% and 
26%. At least moderate necrosis or fibrosis on myocardial biopsy and elevated 
N-terminal pro b-type natriuretic peptide were predictive of worse transplant-free 
survival. The highest risk of life-threatening VAs was seen during the first year 
after symptom onset. The cumulative incidence of SCD or any life-threatening 
VA rose to 52% at 12 months after symptom onset and was associated with at 
least moderate fibrosis on myocardial biopsy and higher cardiac troponin at 
presentation. 
In conclusion, SCD and life-threatening VAs have a major role in the clinical 
course of many CS and GCM patients. Clinically and histopathologically, CS and 
GCM share many similarities and their differential diagnostics can be challenging.
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TIIVISTELMÄ
Tutkimuksen tavoitteena oli selvittää sydänperäisen äkkikuoleman ja henkeä 
uhkaavien kammioperäisten rytmihäiriöiden yleisyyttä sydänsarkoidoosissa ja 
jättisolumyokardiitissa. Tavoitteena oli myös tutkia näiden sairauksien kliinis-
patologisia yhtäläisyyksiä.
Kliinisesti merkittävät kammioperäiset rytmihäiriöt ovat yleisiä sekä sydän-
sarkoidoosissa että jättisolumyokardiitissa ja joskus sydänperäinen äkkikuolema 
on näiden sairauksien ensioire. Tätä tutkimusta varten keräsimme tiedot sydän-
sarkoidoosi ja jättisolumyokardiittipotilaista vuodesta 1991 vuoden 2015 loppuun. 
Tietoja kerättiin sekä kansallisesta tutkimusrekisteristä että -kuolinsyyrekiste-
ristä. 
Tutkimus koostui 351 sydänsarkoidoosi- ja 29 jättisolumyokardiittipotilaas-
ta. Ensioireet olivat samankaltaisia molemmissa tautiryhmissä, mutta eteiskam-
miokatkos oli yleisin löydös sydänsarkoidoosissa ja sydämen vajaatoiminta jät-
tisolumyokardiitissa. Sekä sydänsarkoidoosi- että jättisolumyokardiitiryhmässä 
sydänperäinen äkkikuolema oli taudin ensimmäinen oire 14% tapauksista. Äk-
kikuolema oli kuolinmekanismina neljässä viidestä sydänsarkoidoosin aiheutta-
masta kuolemasta ja lähes puolessa jättisolumyokardiitissa. 
Yli puolet alun perin jättisolumyokardiitiksi diagnosoiduista potilaista paljas-
tui uuden evaluaation jälkeen sydänsarkoidoosiksi. Yleisimmin granuloomia ei 
oltu tunnistettu alkuperäisessä patologisessa tutkimuksessa tai tunnistamisesta 
huolimatta tapaus luokiteltiin jättisolumyokardiitiksi. Alun perin jättisolumyo-
kardiitiksi klassifioitujen sydänsarkoidoosipotilaiden 5-vuotisennuste ilman sy-
dänsiirto oli parempi verrattuna jättisolumyokardiittipotilaisiin. 
Sydänsarkoidoosissa elossaoloennuste elinaikana diagnosoitujen potilaiden 
osalta 10 vuoden kohdalla oli 87%. Sydämen magneettitutkimuksessa todettava 
laaja-alainen jälkitehostuma, alentunut oikean kammion ejektiofraktio ja kam-
mioväliseinän ohentuma olivat huonoja ennusmerkkejä. 
Jättisolumyokardiitissa elossaoloennuste 5 vuoden kohdalla oli 67% ja elos-
saoloennuste ilman sydänsiirtoa oli 26%. Henkeä uhkaavien kammioperäisten 
rytmihäiriöiden insidenssi oli korkein ensimmäisen vuoden aikana. Sydänlihas-
biopsian löydökset sekä sydämen biomarkkerit taudin alkuvaiheessa olivat mer-
kittäviä ennusteeseen ja rytmihäiriöriskiin assosioituvia tekijöitä.
Yhteenvetona, henkeä uhkaavat kammioperäiset rytmihäiriöt ja äkkikuole-
man riski muodostavat merkittävän kliinisen ongelman sekä sydänsarkoidoosissa 
että jättisolumyokardiitissa. Sydänsarkoidoosi ja jättisolumyokardiitti muistutta-




Sarcoidosis is an inflammatory disease characterized by granulomatous 
inflammation in virtually any organ.1 Of all possible organ involvements, 
cardiac sarcoidosis (CS) is the most malignant manifestation and is associated 
with impaired survival.2 Giant cell myocarditis (GCM) is a rare inflammatory 
cardiomyopathy and early studies depicted it as a very aggressively progressing 
disease with high rates of mortality and cardiac transplantation.3,4 Later studies 
have suggested that the disease spectrum might be broader and that modern 
therapeutics may improve survival.5–7
CS and GCM share clinical and histopathological features.4 Heart failure 
(HF) is the most common presenting clinical manifestation of GCM,3,6 whereas 
high-grade atrio-ventricular (AV) conduction disturbances are typically the most 
prominent first signs of clinical CS.8,9 The occurrence of sudden cardiac death 
(SCD) and life-threatening ventricular arrhythmias (VA) (sustained ventricular 
tachycardia (VT) and ventricular fibrillation (VF)) are common in both CS9–12 and 
GCM.3,4,6,13 In CS, sustained VT or VF can be the main presenting manifestation 
in 33% of cases9 and early studies combining autopsy and clinical registries of CS 
reported SCD as the main presenting clinical manifestation in 11–17% of cases 
in CS.14,15 In GCM, life-threatening VAs have been reported as first manifestation 
in 14 to 32% of cases.3,4,6 The long-term arrhythmic risk is also significant in 
both diseases.3,6,11,13,16,17 It is thus obvious that the treatment of life-threatening 
VAs and the prevention of SCD present major challenges in both CS and GCM. 
VAs are mostly linked to re-entry associated with myocardial scarring,18–21 but 
other arrhythmic mechanisms, e.g., those linked to active inflammation, play a 
role as well.22–26 There are no in-depth analyses of life-threatening VAs in GCM 
and data on their true incidence is limited. Knowledge is based on incidental case 
reports and a few small series3,5,6,13 reporting outcome-data regarding VAs. In CS, 
numerous contemporary studies do report SCD figures in CS,9,11,12,27–30 but they 
all suffer from the limitation that mostly only symptomatic, lifetime identified 
patients were studied, masking the true frequency of SCD in CS. 
The Myocardial Inflammatory Diseases in Finland (MIDFIN) study group, 
focusing on the research of CS and GCM, was established in 2008 and a nationwide 
registry of CS and GCM patients was set up. My research in the MIDFIN group 
started in 2013. Life-threatening VAs in CS and GCM constitute the main theme of 
my thesis. I set out to study their incidence and predictors, as well as to describe the 
overall prognosis of these diseases in the era of modern HF-, anti-arrhythmic- and 
immunosuppressive therapy. During the work I also focused on the relationship 
and differential diagnostics of CS and GCM.
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2 REVIEW OF THE LITERATURE
2.1 Etiology and pathogenesis 
2.1.1 Sarcoidosis
Sarcoidosis is a disease characterized by the presence of inflammatory non-
caseating epithelioid granulomas in diseased organs. Sarcoidosis can involve 
virtually any tissue but lungs are the most commonly affected organ.1 Extra-thoracic 
sarcoidosis is present in one-third to half of patients, most commonly in the skin, 
peripheral lymph nodes, eyes, and liver.1,31 The exact pathogenetic mechanism 
and cause of sarcoidosis are still unknown.32 A postulated cause is an aberrant 
immunological reaction toward an as-yet-unknown antigen in a genetically 
susceptible individual.32 The presence of non-caseating granulomas is the cardinal 
histological feature of sarcoidosis. These granulomas consist of tightly formed 
conjunctions of macrophages differentiating into epithelioid- and multinucleated 
giant cells, encircled by lymphocytes.33 These need to be distinguished from 
caseating granulomas seen in tuberculosis and also from other granulomatous 
diseases.34,35 According to a proposed immunopathogenic mechanism, a putative 
antigen is engulfed by circulating dendritic cells, which then mature in lymph 
nodes and present the antigen peptide to activate a T-cell response.33 The ensuing 
response of the CD4+ T-cells is highly T-helper (TH) 1-polarized. This polarization 
is promoted and followed by a complex interplay and upregulation of a myriad 
of cytokines, including interleukin (IL) 2, IL12, interferon gamma, and tumor 
necrosis factor (TNF) alpha, released by both dendritic- and T-cells.33 
The TH1 response is pro-inflammatory, while the TH2 response is characterized 
by a release of cytokines promoting immunoglobulin E and eosinophil activity. The 
TH2 response also releases anti-inflammatory cytokines, such as IL10.36 The TH1 
response is thought to trigger granuloma formation by recruiting macrophages and 
more lymphocytes to the inflammatory site. The inability of regulatory mechanisms 
to suppress the TH1 response might explain the uncontrolled formation of 
inflammatory granulomas in sarcoidosis patients.37 Chronic granulomatous 
inflammation can lead to fibrosis. The specific immunological mechanisms of 
fibrosis generation are unknown but it is proposed that a switch from a TH1- to 
a TH2-dominant cytokine environment, such as IL13 and transforming growth 
factor beta, stimulates fibroblasts and myofibroblasts which are instrumental in 
the development of fibrosis.33 To date, no specific sarcoidosis-causing antigen has 
been unequivocally identified, however. Table 1 lists common proposed triggers 
for the pathogenesis of sarcoidosis. 
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Table 1. Proposed infectious and non-infectious triggers associated with the pathogenesis 
of sarcoidosis








Two meta-analyses,38,39 focusing on the link between infectious agents and 
sarcoidosis, suggested that mycobacteria38,39 and Cutibacterium acnes39 could be 
associated with sarcoidosis. Cutibacterium acnes (formerly Propionibacterium 
acnes), a commensal bacterium of the skin, is the only micro-organism that has been 
successfully isolated from sarcoid lesions.40,41 Various non-infectious environmental 
risk factors have also been identified, such as exposure to both organic and non-
organic aerosols.42,43 For example, exposure to combustible products, such as 
in firefighters, has been associated with increased risk of sarcoidosis.44 There 
seems to be a clear genetic susceptibility for the risk of developing sarcoidosis. A 
multicenter study showed that the relative risk of a sarcoidosis patient to report a 
parent or sibling with sarcoidosis was 4.7 (95% confidence interval (CI) 2.3–9.7).45 
A Danish-Finnish registry-based twin study demonstrated an 80-fold increased 
risk of sarcoidosis in monozygotic and a 7-fold increased risk in dizygotic co-twins 
of affected brothers or sisters.46 Several candidate genes associated with sarcoidosis 
have been identified.45,47,48 Autoimmune diseases including Sjogren’s syndrome, 
systemic lupus erythematosus, thyroid and thymus disorders, inflammatory bowel 
disease, and insulin-dependent diabetes mellitus are reported in up to one fifth 
of sarcoidosis patients.49–51, 52,53
2.1.2 Giant cell myocarditis
The cause for GCM is unknown but as in sarcoidosis, a CD4+ T-cell process is 
suggested as the underlying pathogenetic mechanism.54 It is possible that the 
etiology of GCM is multifactorial with microbial-, autoimmune-, and genetic causes 
all having a role.55 One study found upregulation of multiple genes associated 
with T-cell mediated immune response, especially of the TH1 subset, in two 
GCM patients compared to six controls.56 There are isolated reports associating 
GCM with an infectious microbial trigger. Suggested viral triggers include herpes 
simplex virus,57 coxsackie B2 virus,58 and parvovirus B19.59 Vaideeswar et al. 
reported in a series of 12 GCM patients that three presented with an acute febrile 
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illness and two of them tested positive for leptospirosis.60 Other autoimmune 
disorders are present in 19% of GCM,3,6 supporting the hypothesis of an underlying 
autoimmune mechanism. Though considered a purely myocardial disease, GCM 
has anecdotally been described in concomitance with giant cell polymyositis and 
linked with thymoma, myasthenia gravis and orbital myositis.61–66 Lastly, GCM has 
also been suggested as a manifestation of drug hypersensitivity.67 Inflammatory 
bowel disease was the most common associated autoimmune disease in the 
landmark study by Cooper et al.3
Classical histological features of GCM include widespread myocardial necrosis 
with inflammatory infiltrate consisting of lymphocytes, histiocytes, eosinophils, 
and giant cells in varying proportions.3,68 A histopathological study of eight GCM 
patients suggested a vasculitis-resembling process with inflammatory infiltrates 
encompassing small and medium-sized arteries leading to arterial stenosis and 
obliteration.69
2.2 Epidemiology
2.2.1 Sarcoidosis and cardiac sarcoidosis
The reported incidence and prevalence of sarcoidosis seem to be highest in Nordic 
countries.70,71 In a register-based study from Sweden,71 the incidence was 11.5 per 
100 000. In contrast, in an epidemiological study from Japan, an incidence of only 
1.01 per 100 000 was reported.72 Ethnicity seems to play a role as the reported 
incidence and prevalence rates are consistently higher in African-American 
populations.73,74 In one study from the US, the incidence per 100 000 was 46 in 
African Americans vs. 11 in Caucasians.73 Arkema et al. reported that the prevalence 
of sarcoidosis in Sweden in 2013 was 160 per 100 000.71 A report by Baughman 
et al.74 estimated that the prevalence in the US was 60.18 per 100 000 in 2012. 
Table 2 demonstrates selected epidemiological figures in sarcoidosis. It should 
be noted that methodological pitfalls such as sampling bias and heterogeneity 
in diagnostic methods do complicate the estimation of reported incidence and 
prevalence data.75,76
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Table 2. Selected epidemiological figures of sarcoidosis
Prevalence 49–160/100 000
Incidence 1–46/100 000
Ethnicity More common in African Americans
Geography More common in Nordic countries
Age ≈ 50 years, possibly a two-peaked incidence with first peak at ≈ 30 
years and the second at ≈ 60
Sex Slightly more common in women
Data is based on references70–74,76,77
Whether or not cardiac symptoms are present in the study population has a major 
impact on the reported epidemiological figures of CS.78,79 CS can even manifest 
itself as SCD and these cases are typically not represented in epidemiological 
studies based on clinical registries. The reported detection rates of CS are also 
dependent on the diagnostic criteria used in each study (see also section 2.6.1). The 
most commonly applied sets of criteria have been the ones recommended by the 
Japanese Ministry of Health and Welfare (JMHW) and the Japanese Circulation 
Society (JCS),80–82 the Heart Rhythm Society (HRS),83 and the World Association 
of Sarcoidosis and Other Granulomatous Diseases (WASOG).84 The HRS and 
WASOG criteria are nearly identical but differ significantly from the JMHW/JCS 
criteria, which have also evolved over time.
The frequency of symptomatic CS in patients diagnosed with extra-cardiac 
sarcoidosis is often cited as approximately 5%,83,85–87 with a variation from 1% to 
16% between studies.78,88–90 Asymptomatic cardiac involvement in sarcoidosis is 
much more common. In a study of 84 consecutive autopsied sarcoidosis patients, 
CS was present in 23 (27%) cases.91 In another more recent study by Webb et al.,92 
CS was present in up to 38 (45%) of 84 consecutive autopsied decedents with 
sarcoidosis. Of note, African Americans comprised 95% of the study cohort.92 It 
should be noted that CS is probably more likely present in fatal sarcoidosis cases; 
hence autopsy studies do present a selection bias. 
Advanced cardiac imaging presents another way of evaluating the frequency 
of cardiac involvement (Table 3). Greulich et al.93 reported that abnormal late 
gadolinium enhancement (LGE) was present in 39 of 155 (25.5%) consecutive 
sarcoidosis patients undergoing cardiac magnetic resonance imaging (CMRI). 
Kouranos et al.94 reported on 321 sarcoidosis patients undergoing CMRI screening 
with CS diagnosed in 96/321 (30%) patients. LGE was present in 93 of these 
96 patients. When an unselected population of systemic sarcoidosis is screened 
for CS, the yield is indeed dependent on the selected screening methods. For 
example, Darlington et al.90 reported that 22 of 1017 (2%) consecutive sarcoidosis 
patients screened for CS by routine electrocardiography (ECG) and inquiries about 
cardiac symptoms were diagnosed with CS. Eleven of these 1017 (1%) had cardiac 
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symptoms, and an additional 11 (1%) asymptomatic CS patients presented with 
an abnormal ECG.  
Table 3. Prevalence of abnormal LGE on CMRI indicative of CS in patients with systemic sarcoidosis 
undergoing screening for CS.
Study Number of patients % of patients with abnormal LGE
Prospective studies evaluating LGE presence in unselected sarcoidosis populations
Cheong et al. 200995 31 26%
Patel et al. 200996 81 26%
Martusewicz-Boron et al. 201689 201 24%
Kouranos et al. 201794 321 29%
Puntmann et al. 201797 53 34%
Stanton et al. 201798 46 22%
Retrospective studies including sarcoidosis patients with suspected CS
Smedema et al. 200578 58 33%
Greulich et al. 201393 155 26%
Crouser et al.201499 50 45%
Nadel et al. 2015100 106 30%
Murtagh et al. 201628 226 20%
Smedema et al. 2018101 84 32%
Flamee et al. 2020102 114 35%
CMRI indicates cardiac magnetic resonance imaging; CS, cardiac sarcoidosis; LGE, late gadolinium 
enhancement
Sarcoidosis confined to the myocardium, i.e., isolated CS, is a subset of CS where 
diagnostics can be especially challenging. The reported prevalence of isolated CS 
varies widely, being dependent on the studies performed to exclude extracardiac 
sarcoidosis.4,9,103,104 Isolated CS can also present with SCD and escape clinical 
registries.105 Routine clinical examinations, chest X-rays and laboratory tests 
may fail to detect extracardiac involvement in 57% to 67% of cases.4,9 In these 
patients with clinically isolated CS, advanced imaging with CMRI, chest-computed 
tomography (CT), or 18F-fluorodeoxyglucose positron emission tomography 
(18F-FDG PET) often expose extracardiac involvement. A report from our group 
(also based on the MIDFIN registry) concluded that 32% of 57 CS patients had 
sarcoidosis confined to myocardium even after assessment with 18F-FDG PET 
during their early diagnostics.103 In contrast, a prospective study from Canada, also 
utilizing 18F-FDG PET, reported a notably smaller proportion of patients (3.2%) 
with isolated CS.104 In an autopsy study, Tavora et al.105 concluded that granulomas 
outside the heart could not be detected in 10 out of 25 (40%) victims of CS-related 
sudden death. The detection rates of CS are growing. In the US, the percentage of 
patients who had HF with CS requiring cardiac transplantation increased five-fold 
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from 0.1% (from 1994 to 1997) to 0.5% (from 2010 to 2014).106 The advancements 
of cardiac imaging, in addition to improved awareness of CS, probably explain 
the growth in the detection rates of CS.107 
In sarcoidosis, the average patient is in their fifties at the time of diagnosis.71,72,88 
A two-peaked incidence rate, especially in females, was reported in a Japanese 
population with the first peak at 25–34 years and the second at 60–64 years,72 
with very few patients younger than 20 or older than 80. Sarcoidosis is usually 
considered slightly more common in women72,88 but contradictory data reporting 
male dominance also exists71. The age and sex distribution of CS do not differ 
from the demographics of sarcoidosis in general. In a Japanese study with 95 CS 
patients,8 the mean age was 51±13 in patients diagnosed during their lifetime and 
57±15 in patients diagnosed at autopsy with overall female predominance (65%). 
Females were also older at diagnosis than males (56±11 vs. 46±16; p=0.0004). In 
a nationwide series of 110 CS patients from Finland, the mean age of all patients 
was 51±9 with 65% of them being female.9 These 110 patients were derived from 
the MIDFIN registry and are also a subgroup of the study population presented 
in this thesis. Studies reporting male predominance in CS also exist.4,108
2.2.2 Giant cell myocarditis
Earlier reports depict GCM as an extremely rare disease. GCM was first 
reported in 1905109 and before the utilization of endomyocardial biopsy (EMB), 
the diagnosis was uniformly made at autopsy or after cardiac transplantation. 
The first reported case of improvement by immunosuppressive therapy was in 
1987.110 In the landmark study by Cooper et al.3 in 1997, a total of 63 cases of GCM 
from 49 medical centers in 16 countries were identified. In one series of 4738 
consecutive patients with EMB for clinically suspected myocarditis or dilated 
cardiomyopathy (DCM), GCM was diagnosed in 10 cases (0.2%).111 Davies et al. 
reported that unexpected GCM was detected in 7 out of 340 consecutive (2%) 
explant studies after cardiac transplantation.112 In a report of 174 consecutive 
patients with suspected myocarditis referred to a tertiary center for arrhythmias 
and cardiac transplantation over a 13-plus-year time period, GCM was diagnosed 
in five (3%) cases.113
Two reports from Finland include epidemiological data on GCM.114,115. Kytö 
et al. reported in 2005 that, after re-analysis, GCM was diagnosed in eight of 
142 consecutive autopsy cases where the initial cause of death was recorded 
as myocarditis. These cases were detected from the national cause-of-death 
registry from 1970 through 1998.114 In 2012 Kandolin et al. reported a series of 
32 consecutive GCM patients in Finland.6 The mean age was 49.5±11 at diagnosis 
in patients with a lifetime diagnosis from biopsy and there was a female (69%) 
predominance in the full cohort. In 2015, Kandolin updated the figures for GCM 
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describing 49 patients identified at Helsinki University Hospital between 1991 
and 2014.115 These patients6,115 are also included in studies II and III of the present 
thesis. As described and detailed in the results of my work, all GCM cases of the 
MIDFIN registry were retrospectively re-evaluated in 2018, and a considerable 
part of the early GCM diagnoses was converted to CS (see results, section 5.1 and 
studies IIb, IIIb, IV, and V). Thus the previously reported figures6,115 are not fully 
valid and must be interpreted cautiously. The mean age of patients in the landmark 
study of Cooper et al. in 1997 was 42.6±12.7 with a roughly equal number of men 
and women (33 vs. 30, respectively).3
2.3 Clinical manifestations in cardiac sarcoidosis
CS can be completely asymptomatic and might only be detected by cardiac 
imaging made either routinely or for ECG abnormalities in a patient with systemic 
sarcoidosis. The consequences of CS are determined by the location and extent of 
granulomatous infiltration and/or subsequent scarring in the heart.14,105 The most 
commonly reported clinical manifestations of CS are AV conduction disturbances, 
VAs, and ventricular dysfunction. Typical symptoms therefore are syncopal 
episodes, palpitations, and dyspnea with exercise intolerance due to HF. However, 
the symptoms and clinical findings range from incidental ECG abnormalities90 
to even SCD as the first manifestation in a previously healthy person.105 From a 
real-life clinical point of view, it should be noted that the various manifestations 
of CS typically overlap and co-exist in a single patient, e.g., AV block (AVB) with 
HF and/or VAs.12
2.3.1 Conduction disturbances
AV conduction defect is the most common evident clinical manifestation of CS. 
Reported rates of second degree or complete AVB in CS vary from 7% to 45%.8,9,78,116 
Sarcoid granulomas and subsequent scarring in the basal ventricular septum, 
where the AV conduction system is vulnerable, probably account for the majority 
of AVBs seen clinically.14,105 
As patchy sarcoid infiltration can affect any part of the cardiac conduction 
system, many kinds of impaired impulse transmission can be seen, varying from 
complete AVB to intraventricular conduction defects.117,118 AVB can also occur only 
during exercise.119 Ischemia from granulomatous infiltration of the nodal artery is 
a less common cause of AVB.120 CS should be suspected whenever an unexplained 
AVB in a relatively young patient is encountered.121,122 In a study of 32 consecutive 
18–60-year-old patients with an unexplained AVB, CS was subsequently diagnosed 
in 11 individuals (34%).121
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2.3.2 Arrhythmias
VAs are common in CS and range from frequent premature ventricular extrasystoles 
to unexpected SCD due to VF. In a series of 15 consecutive patients with biopsy-
proven thoracic sarcoidosis and no cardiac symptoms except palpitations in one 
patient, 24-hour ambulatory ECG recordings showed VAs in 4/15 (40%) patients 
including > 10 premature ventricular extrasystoles per hour in two patients, non-
sustained VT in one patient, and sustained VT in one patient.123 In a study of 38 
sarcoidosis patients, of whom 12 had CS, > 100 premature ventricular extrasystoles 
per 24 hours were seen in 67% of CS patients compared to 8% of sarcoidosis 
patients with no cardiac involvement.124 In 110 Finnish CS patients, sustained VT 
or VF was the first clinical manifestation of CS in one third of cases.9 Nery et al. 
studied 14 patients with unexplained non-ischemic VT and found that CS was the 
underlying etiology in four (28%) cases.125 In another study by Tung et al., CS was 
ultimately diagnosed in 18 (17%) of 103 consecutive patients referred for work-up 
of unexplained cardiomyopathy and VAs.126 A recent study showed that CS was 
diagnosed in 4.5% of patients presenting with non-ischemic unexplained VAs.127 
SCD can be the first and only clinical manifestation of CS.14,15,128 In an autopsy study 
from 1977,14 SCD was the first sign of CS in 10 out of 89 (11%) cases. In another 
study from 1981,15 Fleming and Bailey reported that out of 197 CS patients seen 
in a 10-year period, SCD was the first presenting manifestation in 34 (17%) cases. 
In contrast, another more recent autopsy study of 17 consecutive autopsied CS 
patients reported that all 11 patients with antemortem clinical data had symptoms 
prior to death but all escaped a lifetime diagnosis.128 These symptoms varied from 
palpitations (4 out of 11) to HF combined with AVB (one out of 11).
Although atrial fibrillation (AF), atrial tachycardia and other supraventricular 
arrhythmias are commonly seen during follow-up of CS patients,129 they are rarely 
the first sign of CS. None of the 110 consecutive CS patients reported by Kandolin 
et al.9 had supraventricular arrhythmias as the main presenting manifestation. 
Weng et al.130 reported that supraventricular arrhythmias were the predominating 
manifestation of CS in one out of 33 (3%) cases. On rare occasions, atrial CS can 
also manifest as sick sinus syndrome or even atrial standstill.131,132
Section 2.5 of this thesis reviews the mechanisms and characteristic of VAs in 
CS and GCM in more detail.
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2.3.3 Heart failure
Ventricular failure in CS results from widespread myocardial inflammation 
and subsequent scarring. The presence of diastolic ventricular dysfunction is 
more common in pulmonary sarcoidosis patients than healthy controls and, 
although possibly of a multifactorial origin, it can be the first sign of cardiac 
involvement preceding systolic dysfunction.133,134 HF with reduced ejection fraction 
is a sign of advanced CS and widespread involvement of the ventricles.14 Besides 
resulting from direct myocardial destruction, HF can be a consequence of AV 
valve regurgitation from granulomatous infiltration of papillary muscles.14 Focal 
inflammation can also lead to ventricular aneurysms (see Figure 1).6,135 Although 
left ventricular (LV) or biventricular failure is the most common finding, CS can 
also cause isolated or predominant right ventricular (RV) failure mimicking 
arrhythmogenic right ventricular cardiomyopathy (ARVC).136–140 Occasionally, 
RV failure can be a consequence of pulmonary hypertension that is caused by 
granulomatous infiltration of pulmonary vasculature, even in the absence of 
extensive pulmonary fibrosis.141–143
Figure 1. Ventricular aneurysm in cardiac sarcoidosis. A left ventriculogram in diastole (left panel) and 
systole (right panel) showing a large ventricular aneurysm (asterisk). Adapted from Kandolin et al. 20136
In an early study from the UK,15 HF was the predominant manifestation of CS in 
17% of cases. Another study from 2001 reported that of 75 Japanese CS patients, 
as many as 36 (48%) had a depressed left ventricular ejection fraction (LVEF) (< 
50%) at presentation.8 In the modern era, with common utilization of advanced 
cardiac imaging and probably earlier detection of CS, congestive HF remains 
the predominant manifestation in 11–18% of cases.9,144 CS can be misdiagnosed 
as idiopathic DCM or, less commonly, as hypertrophic cardiomyopathy.140,145,146 
A recent French nationwide study140 reported that during a 17-year period, 15 
CS patients were diagnosed from explanted hearts only after transplantation. 
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Twelve patients had a pre-transplantation diagnosis of DCM, two were diagnosed 
as hypertrophic cardiomyopathy and one as ARVC. It was concluded that in 77% 
of cases, CS could have been detected with non-invasive imaging techniques.140
During initial evaluation, concomitant AV conduction defects and regional 
ventricular wall thickness abnormalities are clues to suspecting sarcoid 
cardiomyopathy.147 Also, mediastinal lymphadenopathy may serve as a sign of 
CS, although this can sometimes be seen due to mere congestive HF in DCM.146
2.3.4 Syndromes mimicking coronary artery disease 
Chest pain associated with myocardial ischemia on thallium-201 scintigraphy 
without coronary artery obstructions has been reported in sarcoidosis.148 Also, case 
reports of CS presenting as a syndrome mimicking myocardial infarction149,150,151 or 
even takotsubo cardiomyopathy152 exist. Sarcoidosis can affect coronary circulation 
in various ways. Sarcoid granulomas have been demonstrated to directly affect 
epicardial coronary arteries,150,153 and impairment of hyperemic coronary 
circulation in areas of inflammation has also been described.154 The improvement 
of myocardial hyperemic blood flow in inflamed areas after immunosuppressive 
therapy suggests a direct adverse effect of myocardial inflammation on coronary 
vasodilator capacity.154 There are also reports of spontaneous coronary artery 
dissection in CS.151,155,156
2.3.5 Pericardial and valvular abnormalities
Pericardial effusion can be detected in up to 13–19% of CS patients,116,157 but 
CS rarely presents mainly as a pericardial disease.158–160 The most commonly 
seen valvular abnormality is mitral insufficiency,161–164 but lesions of aortic165 
and tricuspid valve166 have also been reported. Mitral insufficiency in CS is 
probably most often due to ventricular dilatation or direct sarcoid involvement 
of the papillary muscles.14,162–164 In the early autopsy studies, papillary muscle 
involvement was present in 13–27% of cases.14,91 Mild mitral insufficiency is not 
uncommon but severe cases with a fatal outcome163 or which necessitate valvular 
replacement162 have also been reported.
2.4 Clinical manifestations in giant cell myocarditis
Figure 2 demonstrates the differences and similarities of clinical characteristics in 
CS and GCM. The spectrum of clinical manifestations in GCM closely resembles the 
signs and symptoms of CS. There are, however, some differences in the distribution 
of the main disease manifestations.4,7 Systolic LV impairment due to aggressive 
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inflammation and myocardial destruction is typical of GCM,3,4,6,7,13 while AVB is 
the most common first sign of CS.4,7,9 Sometimes diastolic LV dysfunction, probably 
caused by LV edema, can be the predominant mechanism of HF in the early course 
of GCM.167 In the landmark multicenter GCM registry study, the main presenting 
manifestations were HF in 75%, VAs in 14%, a syndrome mimicking myocardial 
infarction in 6%, and AVB in 5% of all cases, respectively.3 In 2003, after the 
inclusion of additional cases in the registry, it was reported that the majority 
(64%) of the 73 patients presented with a left sided HF; VT or VF was the main 
manifestation in 32%, and AVB in 15% of cases, respectively.4
In 2015, Maleszewski et al. reported on 26 selected GCM patients who 
had survived for more than one year without transplantation.13 HF was the 
presenting symptom in 15 cases (58%). Recently, Nordenswan et al.7 compared 
the characteristics of 351 CS patients and 28 GCM patients also derived from the 
MIDFIN registry. HF was the presenting manifestation in 50% of GCM vs. 15% 
of CS, while high-grade AVB was the first disease sign in 21% of GCM vs. 43% of 
CS.7 Also, impaired LVEF (≤ 50%) was found at presentation in 81% in GCM vs. 
in 48% in CS. There are other less commonly reported symptoms and findings 
associated with GCM presentation. Vaideeswar et al.60 reported that three out of 12 
patients from an Indian population presented with an acute febrile illness. Larsen 
et al.168 reported six cases of isolated atrial GCM. Four of these patients had AF 
as the main manifestation leading to diagnosis, one had HF and one had SCD.
The time from symptom onset to presentation at hospital and/or diagnosis is 
typically shorter in GCM than in CS. The reported median time from symptom 
onset to presentation was three weeks in the study by Cooper et al.3 GCM typically 
has a much more aggressive clinical course than CS. However, GCM can have a 
protracted disease course,13,169 while CS can present as fulminant myocarditis 
with rapid deterioration.170–172 
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Figure 2. Comparison of clinical characteristics in cardiac sarcoidosis and giant cell myocarditis. Data 
from references3–5,7–9,14,15,78,129,144 
 
AVB indicates atrioventricular block; HF: heart failure; SCD: sudden cardiac death; VA: ventricular 
arrhythmia
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2.5 Pathogenesis, mechanisms, and characteristics of 
ventricular arrhythmias in cardiac sarcoidosis and giant 
cell myocarditis
2.5.1 Cardiac sarcoidosis
The majority of sustained monomorphic VAs seen in CS are scar-related 
monomorphic VTs caused by non-uniform and slow impulse propagation in scarred 
myocardium, leading to re-entry circuits.18,19,22 Patterns of myocardial scarring in 
CS have been depicted across studies by gross anatomy,105,14,91 imaging,173–175 and/
or electroanatomical mapping.174–177 Virtually any part of the right, left, or both 
ventricles can be affected. Isolated RV involvement, however, is rare with only 
2/25 cases reported in one autopsy study.105 In the LV, scarring tends to be patchy 
with a predilection for the septum, anterior wall, and perivalvular regions.174,176 
In the RV, scarring detected by electroanatomical mapping is characterized by 
confluent regions of endo- and epicardium, with no predilection for any particular 
RV region.176 Somewhat contradictory to this, Jefic et al. suggested a predilection 
for basal RV involvement resulting in peritricuspid re-entry.177
A preferentially mid-wall or epicardial scarring pattern was found in one CMR 
study, although one third of patients also had subendocardial LGE involving at 
least one LV segment.173 The predilection for scarring of the epicardium is reflected 
by the frequent need for an epicardial RFCA to successfully abolish VTs.176–179 
Muser et al. described the characteristics of electroanatomical substrate in 42 CS 
patients undergoing high-density electroanatomical mapping and radiofrequency 
catheter ablation (RFCA), and compared these findings with CMRI and 18F-FDG 
PET results.174 They reported a predominance of abnormal substrate in the basal 
septum and perivalvular regions. They also showed that abnormal intracardiac 
electrograms (EGM) (generally considered potentially relevant targets for RFCA) 
were most likely to be found in areas with higher scar transmurality on CMRI. 
These areas also showed less evidence of active inflammation on 18F-FDG PET. 
Multiple forms of monomorphic VTs in one patient are common and could be the 
result of heterogeneous and diffuse scarring, giving rise to multiple VT re-entry 
circuits. Typically, a median of three different forms of VT can be induced during 
programmed ventricular stimulation (PVS).174–176
While the contribution of myocardial necrosis and replacement fibrosis to 
arrhythmias in CS is well understood, the role of active inflammation is less clear. 
In lymphocytic myocarditis, polymorphic and irregular VAs were more commonly 
seen in the inflammatory phase.180 These polymorphic VAs are the result of various 
mechanisms ultimately leading to automaticity and triggered activity.181 Although 
similar data for CS does not exist, it can be speculated that pathophysiological 
mechanisms directly related to inflammation might be responsible for the 
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polymorphic VAs encountered in CS patients as well. In a study of 118 CS patients, 
inflammation detected by 18F-FDG uptake with concomitant perfusion defects 
identified patients at higher risk of VAs.182 Contradictory to this, Banba et al. 
could not demonstrate a correlation between inflammatory activity (detected by 
Gallium-67 scintigraphy) and new onset VTs.183 Also, in CS patients undergoing 
electroanatomical mapping, abnormal EGMs are more likely to be found in scarred 
myocardium than areas with active inflammation.174 This indirectly suggests that 
scar, rather than inflammation, might be the main driver for arrhythmias. It 
should be noted that active inflammation and scar-formation often co-exist and 
re-entry circuits can also be formed during ongoing active inflammation and 
granuloma formation (the inflammation-fibrosis continuum).22,174 Re-entry is 
the most probable underlying arrhythmia mechanism, even in CS patients with 
active myocardial inflammation,22 but whether the causative slowing of conduction 
is mainly due to areas of scarring or inflammation remains unclear. Lastly, 
inflammation-induced ventricular ectopy can act as a trigger for scar-related re-
entrant VTs.23 A rarer mechanism of VAs in CS could be related to inflammation-
induced myocardial ischemia.150,153,154,184 VT related to the Purkinje system has also 
been described with a narrower QRS duration than in scar-related VTs.18
2.5.2 Giant cell myocarditis
Compared to CS, less data on the mechanisms of VAs in GCM exists but given 
their histopathological and clinical similarities, it can be assumed that the 
electrophysiological phenomena underlying arrhythmias could be alike. Myocardial 
necrosis and the resulting replacement fibrosis are in general more extensive in 
GCM, giving rise to several re-entrant circuits. Reports of GCM patients undergoing 
electrophysiological study and/or VT RFCA describe successful induction of 
VTs by PVS and successful activation mapping of the tachycardia circuits, both 
indicative of a re-entry mechanism.20,21 Graner et al. reported that in nine GCM 
patients a median of three (range 1–6) different VT morphologies per patient were 
encountered.21 There are some case studies reporting that immunosuppressive 
therapy reduced incessant arrhythmias in acute settings,25,26,185 suggesting a 
pathophysiological mechanism linked to inflammation in these cases. 
Plakoglobin and other desmosomal proteins are responsible for myocardial 
intercellular linking, and their abnormalities are a key component in the 
pathophysiology of ARVC, a highly arrhythmogenic hereditary cardiac disease.186 
Defects in these linking sites can lead to cell death and progressive fibro-fatty 
replacement with strands of surviving myocardium acting as the media for re-
entrant arrhythmias.186 A disruption and reduced expression of these proteins 
are seen in both GCM and CS.187 This might explain the resemblance of clinical 
arrhythmias seen in CS and GCM to those in ARVC.
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2.6 Diagnostics of cardiac sarcoidosis
2.6.1 Diagnostic criteria and screening of cardiac sarcoidosis
The definitive diagnosis of CS stems from verification of sarcoid histology in 
a myocardial sample obtained, for example, by EMB, during cardiac surgery 
or upon studying the native heart after transplantation or at autopsy. In 1993 
JMHW published guidelines on the diagnosis of CS. 81 They proposed in addition 
to a “histological diagnosis group” a “clinical diagnosis group,” where a set of 
abnormalities in ECG, imaging, and other cardiac parameters combined with 
sarcoid histology obtained from extra-cardiac tissue was required. In 2006 
JMHW revised these guidelines.82 A histological verification was no longer 
required for the “clinical” diagnosis of CS. These guidelines were widely adopted 
despite the evidence that the sensitivity of the criteria is too low.188,189 In 2017 
the JCS further revised the 2006 guidelines. The key alterations were, first, the 
inclusion of findings on either 18F-FDG-PET or CMRI in the “major criteria” 
category, and second, the addition of criteria for isolated CS.80 In 2014 HRS 
published an expert consensus statement on the diagnosis and management of 
VAs associated with CS.83 They also propose two pathways for diagnosing CS—a 
“histological” diagnosis from myocardial biopsy or a “clinical” diagnosis where 
an extracardiac histological diagnosis of sarcoidosis is combined with clinical 
and/or imaging findings consistent with CS. Also in 2014, WASOG developed a 
new sarcoidosis organ assessment instrument where, based on the consensus of 
a panel of sarcoidosis experts, criteria for cardiac involvement in the absence of 
myocardial histology were set.84 According to the instrument, an extracardiac 
histological confirmation of sarcoidosis is necessary and then, based on different 
clinical and imaging findings including LGE-CMRI and 18F-FDG PET if available, 
the diagnosis of CS is defined as probable (50–89% likelihood) or possible (< 50% 
likelihood). Table 4 summarizes the current diagnostic criteria of CS proposed by 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Recommendations concerning screening patients with extracardiac sarcoidosis 
for cardiac involvement are available from the HRS and the American Thoracic 
Society.83,190 The HRS statement recommends routine initial screening by ECG, 
echocardiography, and inquiry of cardiac symptoms.83 The experts acknowledge, 
however, that the data backup is very limited; the recommendation was based 
only on two79,191 small observational studies. In contrast to the HRS statement, 
the American Thoracic Society practice guidelines recommend only baseline 
ECG for sarcoidosis patients without cardiac symptoms or signs; these experts 
do not endorse routine echocardiography or 24-hour ECG recordings for screening 
purposes.190 CMRI might be of significant additional value, as suggested by a 2017 
study of 321 extracardiac sarcoidosis patients.94 Using the HRS criteria as the 
standard for the presence of CS, CMRI was the most valuable screening tool with 
sensitivity and specificity of 96.9% and 100%, respectively.94 In most institutions, 
however, issues with availability and cost-effectiveness prevent the wide-scale 
use of CMRI for routine screening. Mehta et al. compared the sensitivity and 
specificity of widely available diagnostic methods (query of cardiac symptoms, 
ECG, ambulatory ECG, and echocardiogram) against CMRI and 18F-FDG PET 
suggestive of CS in 62 patients with extracardiac sarcoidosis.79 An abnormal 
ambulatory ECG appeared to perform best with diagnostic sensitivity and 
specificity of 50% and 97%, respectively. If any of these baseline diagnostic tests 
were positive, the sensitivity and specificity were 100% and 87%, respectively.
Finally, the definitive diagnosis of isolated CS can be extremely difficult and 
requires a high index of suspicion and sometimes repeated biopsies. Sarcoid 
granulomas are typically focally present in the myocardium, significantly 
impairing the sensitivity of a single non-targeted EMB.96,107,188,192 The latest Japanese 
guidelines allow a diagnosis of isolated CS without myocardial histology when a 
set of clinical and imaging findings is fulfilled.80 This approach is susceptible to 
criticism, however, as there are no cardiac findings, either clinical, laboratory, or 
imaging-based, that are specific to CS. 
2.6.2 Biomarkers
Angiotensin converting enzyme (ACE) levels are elevated in 60% of patients with 
sarcoidosis but lack specificity and sensitivity to be reliably used in the diagnosis 
or exclusion of sarcoidosis.193 In suspected CS, elevated serum ACE activity, 
especially in combination with depressed LVEF, is linked to a higher likelihood 
of diagnostic EMB.194 Elevated levels of high-sensitivity cardiac troponin I or T 
(hs-cTnT/I) indicate ongoing myocardial damage and can be useful markers of 
disease activity in CS.195,196 Baba et al. showed that elevated hs-cTnT was indicative 
of active inflammation as judged by correlation with 18F-FDG uptake on PET.195 
A study including 62 CS patients showed that hs-cTnT or hs-cTnI normalized in 
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67% of patients after initiation of immunosuppressive therapy.196 Importantly, hs-
cTnT/I was normal in 47% of patients at presentation, underlining the fact that 
normal troponin levels, even in untreated CS, are not uncommon.196 
N-terminal pro b-type natriuretic peptide (NT-proBNP) is an unspecific 
indicator of myocardial wall stretch and neurohormonal activation.197 Elevated 
NT-proBNP was accurate in identifying patients with cardiac involvement in a 
study of 150 Japanese sarcoidosis patients.198 Concentrations of the soluble form of 
IL2 receptor have been shown to be elevated in serum and bronchoalveolar lavage 
of sarcoidosis patients.199 Levels are elevated in patients with active sarcoidosis 
decreasing with therapy initiation, making soluble IL-2 receptor a potential 
marker of disease activity.200 A multiple biomarker approach incorporating all 
the aforementioned biomarkers in diagnostics and risk stratification of sarcoidosis 
has also been reported.201 The study concluded that NT-proBNP was useful in 
detecting cardiac involvement, ACE and soluble IL-2 receptor concentrations were 
higher in CS patients with concomitant extracardiac sarcoidosis and that hs-cTnI 
predicted fatal arrhythmias in CS.201
2.6.3 Echocardiography
Echocardiography is a useful first line imaging modality in suspected CS as it is 
non-invasive, widely available, and almost always performed during a cardiac 
outpatient visit. The HRS expert statement recommends echocardiography 
as a routine screening tool for CS in asymptomatic patients with extracardiac 
sarcoidosis.83 In contrast, however, the more recent American Thoracic Society 
practice guideline advices against echocardiographic screening if cardiac 
symptoms and signs are absent and the ECG is normal.190 Importantly, CS cannot 
be ruled out by echocardiography as findings can be normal in as many as 54–75% 
of confirmed CS.79,202 The positive predictive value of an abnormal echocardiogram 
for CS in patients with extracardiac sarcoidosis was 83.9% in a study published 
in 2017.94 Echocardiographic findings include LV dilatation, LV and RV systolic 
and diastolic dysfunction, regional wall-motion abnormalities not confined to a 
specific coronary artery territory, localized thinning or thickening of ventricular 
wall, especially of the basal septum, and ventricular aneurysms.203,204 Although 
most findings are nonspecific for CS, thickness abnormality of the basal septum 
is considered more strongly suggestive of CS.147,205,206 Ventricular septal thickening 
is probably related to granulomatous infiltration and edema in the acute phase 
whereas subsequent scarring is responsible for the abnormal thinning.147,206 Figure 
3 demonstrates thinning of the basal septum on echocardiography. Advanced 
echocardiographic methods, such as speckle tracking and strain imaging can 
be useful in early detection of subclinical cardiac involvement in sarcoidosis 
patients.207,208 Echocardiography is an important follow-up tool in patients with 
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established CS as impaired LVEF, as well as impairment of initially normal LVEF, 
are predictors for adverse cardiac events.27
Figure 3. Thinning of the basal septum in cardiac sarcoidosis. Left panel: parasternal long-axis view 
showing abnormal thinning of the basal septum (white arrow). Right panel: Apical four-chamber view 
showing aneurysmatic thinning of the basal septum (white arrow).
2.6.4 Cardiac magnetic resonance imaging
Together with 18F-FDG PET, CMRI is the imaging modality of choice in the workup 
of suspected CS.83,209 Several different image acquisition protocols are used during 
a CMRI scan with each giving specific information. Cine-imaging is a very accurate 
method for delineating cardiac structure and ventricular function.210 Quantitative 
measurements of ventricular volume, function and wall thickness can be made 
more accurately than with two-dimensional echocardiography. Structural and 
functional abnormalities are similar with those seen in echocardiography. In 
LGE imaging, the gadolinium chelate tracer distributes in the extracellular 
matrix of the myocardium in various patterns depending on the underlying 
pathological condition. Myocardial inflammation and myocyte destruction, as 
well as myocardial fibrosis due to collagen deposition, lead to an increase in the 
extracellular matrix and thus result in LGE.211 No LGE pattern is pathognomonic 
for CS but typical findings include patchy LGE involvement, unrelated to coronary 
artery distribution, in basal and lateral segments and sometimes also in the RV 
(Figure 4).96,202,212 LGE is especially common in the basal ventricular septum 
and is typically subepicardial or intramural, but can also be confined in the 
subendocardium or may even be transmural.213 In T2-weighted CMRI, edema is 
detected by an abnormal ratio of signal intensity of suspected myocardium and 
skeletal muscle.214 Quantitative T1 and T2 mapping has been proposed to increase 
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Figure 4. Cardiac magnetic resonance imaging showing abnormal late gadolinium enhancement 
(LGE).  
Left panel: long-axis slice where LGE is present in a widespread, patchy, mid-to-epicardial 
fashion (arrows). Right panel: short-axis slice showing confluent epicardial LGE extending into 
the interventricular junction and right ventricle (arrows). 
 
The diagnostic performance of CMRI in detecting CS depends on whether JMHW/JCS,80–82 HRS,83 
or WASOG84 criteria are used as the reference. In a study of 321 patients with extra-cardiac 
biopsy proven sarcoidosis, and HRS expert consensus statement criteria as “gold standard”, 
Kouranos et al.94 calculated a sensitivity and a specificity of 97% and 100%, respectively, for 
CMRI in detecting CS. This translated to an area under the curve of 0.984 and positive and 
negative predictive values of 100% and 99%, respectively. Also, LGE was absent in only three 
(3%) of 96 patients with CS. In a meta-analysis of 649 patients, Zhang et al. compared the 
diagnostic efficacy of CMRI against the JMHW criteria and concluded an overall sensitivity and 
specificity of 94% and 85% respectively.218 It is noteworthy that LGE on CMRI and 18F-FDG uptake 
on PET are both listed as criteria for a clinical diagnosis of CS in the HRS consensus statement 
and as “major criteria” in the JMHW guidelines.80,83 An important limitation of the above 
studies94,218 is that the diagnostic performance of CMRI was tested against these sets of 
diagnostic criteria instead of the gold standard—myocardial histology. This explains the nearly 
perfect diagnostic performance of CMRI for the detection of CS in patients with proven 
extracardiac sarcoidosis in the study by Kouranos et al.94 
 
CMRI can be useful when planning for VT RFCA as abnormal intracardiac electrograms are often 
seen in ventricular segments with LGE and these areas can be targeted for detailed 
electroanatomical mapping.174,219 Finally, some reports suggest that LGE could be used for 
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The diagnostic performance of CMRI in detecting CS depends on whether JMHW/
JCS,80–82 HRS,83 or WASOG84 criteria are used as the reference. In a study of 321 
patients with extra-cardiac biopsy prove  sarcoidosis, and HRS expert consensus 
statement criteria s “gold standard”, Kouranos et al.94 calculated a sensitivity
and a specificity of 97% d 100%, respectively, for CMRI in detecting CS. This 
translated to an area under the curve of 0.984 and positive and negative predictive 
values of 100% and 99%, respectively. Also, LGE was absent in only three (3%) of 
96 patients with CS. In a meta-analysis of 649 patients, Zhang et al. compared the 
diagnostic efficacy of CMRI against the JMHW criteria and concluded an overall 
sensitivity and specificity of 94% and 85% respectively.218 It is noteworthy that 
LGE on CMRI and 18F-FDG uptake on PET are both listed as criteria for a clinical 
diagnosis of CS in the HRS consensus statement and as “major criteria” in the 
JMHW guidelines.80,83 An important limitation of the above studies94,218 is that 
the diagnostic performance of CMRI wa  tested against these sets of diagnostic 
criteria instead of the gold standard—myocardial histology. This explains the 
nearly perfect diagnostic performance of CMRI for the detection of CS in patients 
with proven extracardiac sarcoidosis in the study by Kouranos et al.94
CMRI can be useful when planning for VT RFCA as abnormal intracardiac 
electrograms are often seen in ventricular segments with LGE and these areas 
can be targeted for detailed electroanatomical mapping.174,219 Finally, some reports 
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suggest that LGE could be used for monitoring treatment effect in CS30,220 The 
prognostic role of CMRI is discussed separately in section 2.11.3.1
2.6.5 18F-fluorodeoxyglucose positron emission tomography
Inflammatory cells exhibit increased glucose metabolism, which can be imaged 
by utilization of 18F-FDG, a glucose analog. Unlike glucose, 18F-FDG is not 
metabolized further but stays in macrophages.221 18F-FDG PET imaging is usually 
complemented with resting myocardial perfusion imaging to recognize areas of 
scarring and their relation to areas of inflammation.221 A hallmark finding in CS 
is focal or multifocal 18F-FDG uptake, suggesting active inflammatory activity, 
especially when seen in areas with abnormal perfusion (see Figure 5).221–223 This 
type of mismatch pattern is, however, not always seen and some patients exhibit 
only multifocal abnormal 18F-FDG uptake. Homogeneously increased 18F-FDG 
uptake alone, especially in the lateral wall, is a nonspecific finding.221,222 Scarring 
without 18F-FDG uptake does not rule out CS as it can represent a “burned out” 
stage where no active inflammation is present.223 Analysis of 18F-FDG PET images 
has mainly been based on visual assessment, but quantitative techniques can also 
be used to measure the standard uptake value, which is the concentration of the 
radioactive tracer corrected by the injected dose and the patient’s weight.223,224
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Figure 5. Perfusion-metabolism mismatch pattern.  
Short-axis 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (bottom row) and 
rest perfusion (top row) images from base (left) towards apex (right) showing a mismatch 
pattern typical of CS. Extensive myocardial uptake of 18F-FDG is seen in an inferoseptal area, 
congruently with decreased rest perfusion. 
 
CS patients very often have extracardiac sarcoidosis.193 The diagnostic value of 18F-FDG PET is 
increased by its ability to identify sites of extracardiac inflammation in the field of view of the 
scan, especially in the lungs and mediastinal lymph nodes (see Figure 6).103,104,107 If EMB is 
undiagnostic but a strong suspicion for CS remains, “hot” mediastinal lymph nodes seen on 18F-
FDG PET should encourage a mediastinal lymph node biopsy to confirm the diagnosis.107 A meta-
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CS patients very often have extracardiac sarcoidosis.193 The diagnostic value of 
18F-FDG PET is increased by its ab lity to identify sites of extra ardiac inflammation 
 the field of v ew f the scan, especi lly in the lungs and m diastinal lymph 
nodes (see Figure 6).103,104,107 If EMB is undiagnostic but a strong suspicion for CS 
remains, “hot” mediastinal lymph nodes seen on 18F-FDG PET should encourage 
a mediastinal lymph node biopsy to confirm the diagnosis.107 A meta-analysis 
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from seven studies and 164 patients reported a pooled sensitivity of 89% and a 
pooled specificity of 78% of 18F-FDG PET in detecting CS.225 A more recent meta-
analysis of 17 studies reported a pooled sensitivity of 84% and a pooled specificity 
of 83%.226 A hybrid strategy combining the diagnostic value of both 18F-FDG PET 
and CMRI has also been proposed and shown to increase the sensitivity and 
specificity of detecting CS.227 A limitation of these studies is, however, the use 
of the JMHW diagnostic criteria as the reference standard, clouding the true 
diagnostic performance of 18F-FDG PET.  
Figure 6. Whole-body 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography images. The left 
panel shows abnormal 18F-FDG accumulation confined to myocardium (isolated cardiac sarcoidosis). 
The right panel shows both myocardial and mediastinal lymph-node 18F-FDG accumulation.
Finally, 18F-FDG PET imaging also gives quantitative information on the extent 
of inflammation and can thus be used to assess the disease severity and the 
treatment response.223,228 Still, experts underline that it is unknown whether 
reduced 18F-FDG uptake after immunosuppressive therapy is associated with 
reduced risk of major cardiovascular events.223
2.6.6 Endomyocardial and extracardiac biopsies
For a definitive diagnosis of CS, a myocardial sample demonstrating typical 
features of sarcoidosis must be obtained. Previous studies have reported that 
in suspected CS, non-targeted EMB results in a definitive diagnosis in only 
about 1 in 5 true cases.96,107,188,192 This is explained by the patchy nature of the 
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inflammatory infiltrates in CS; if they are missed by the bioptome, CS remains 
undetected. The probability of a positive EMB is also higher in more extensive 
myocardial involvement. This was demonstrated by Uemura et al.,188 showing 
that EMB resulted in diagnosis in 36.4% of cases presenting with a DCM-type 
disease compared to only 6.7% of cases presenting with conduction disturbances 
and a preserved LV function. Komoriyama et al. also showed that lower LVEF was 
associated with a higher probability of positive EMB.194 Usually, the RV is primarily 
targeted for EMB96,107,188,192 although, if indicated by imaging findings, LV biopsy 
can also be performed107,229 with comparable complication rates to RV EMB.230
HRS recommends primarily pursuing a clinical diagnosis of CS by obtaining 
a biopsy from extra-cardiac sites, such as the mediastinal lymph nodes or lungs 
if they show evidence of disease activity; the reasoning being the relatively poor 
diagnostic yield of EMB and lower procedural risks of extracardiac biopsies.83 
Kandolin et al. reported that repeated EMBs eventually resulted in a definitive 
diagnosis in 55% of patients with high suspicion of CS.107 The first EMB was 
diagnostic in 10 out of 31 (32%) patients but when EMB was repeated, in some 
cases up to three times, CS could be detected in seven additional patients. 
Importantly, the mediastinal lymph node biopsies exposed sarcoid granulomas 
per attempt much more often than EMB (11 out of 12; 92%). Finally, a small 
study has shown that, in suspected CS, a random biopsy of lungs or mediastinal 
lymph nodes may expose granulomatous inflammation even in the absence of any 
extracardiac 18F-FDG uptake on PET.231
The previously reported figures96,107,188,192 on the yield of non-targeted EMBs 
might not hold true in contemporary diagnostics of CS. Imaging by CMRI or 
18F-FDG PET can increase the diagnostic yield of EMB by revealing the most 
appropriate areas (e.g., RV vs. LV; basal vs. apical septum) to be targeted.107,229 
Higher rates of positive RV EMBs can be expected if there is evidence of RV 
and/or ventricular septal involvement on cardiac imaging.96,182,232 Blankstein et al. 
reported that while the overall proportion of positive EMBs in 48 patients was 
27%, it was 45% in the 20 patients with 18F-FDG uptake on PET.182 Moreover, of 
the six patients with RV 18F-FDG uptake undergoing EMB, CS was detected in 
five (83%). Another study reported that 42% of patients with RV 18F-FDG uptake 
had a positive EMB, compared to only 6% in patients without RV 18F-FDG uptake 
(p=0.024).232 In the study by Patel et al.,96 13 patients underwent EMB, of whom 
eight had LGE on CMRI. Two of the eight (25%) were diagnostic for CS. Of the 
11 patients with negative EMBs, five had no LGE on CMRI and none of the 
remaining six had widespread septal involvement (two had no septal LGE at all). 
Komoriyama et al. showed that higher serum ACE activity was associated with a 
higher probability of a positive EMB.194 When this was combined with low (< 37%, 
median) LVEF, the specificity and positive predictive value for positive EMB were 
as high as 91.2% and 73.7%, respectively. Electroanatomical mapping can also aid 
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in detecting areas relevant for EMB.174,229,233,234 Muser et al. showed that abnormal 
unipolar voltage in areas with normal bipolar voltage correlated with the presence 
of active inflammation on 18F-FDG PET, suggesting that these could be relevant 
targets for diagnostic biopsies.174 Liang et al.234 demonstrated that an abnormal 
EGM at the biopsy site predicted abnormal myocardium with a good sensitivity 
(67%) and specificity (92%), whereas normal EGMs with a voltage of > 5 mV 
signified normal myocardium with no significant diagnostic yield. Lassner et al.111 
proposed myocardial gene expression profiling to increase the diagnostic yield of 
EMB in suspected CS. Distinct gene expression profiles appeared to discriminate 
between patients with histopathological CS and GCM from inflammation-free 
subjects and from those with active myocarditis.
The principles and practice of CS diagnostics at Helsinki University Hospital 
have been detailed in several earlier reports.9,12,107,235 In short, an absolute diagnosis 
from a sample of heart muscle has been the primary goal throughout these works. A 
diagnosis corresponding to the “probable CS” category by HRS83 and WASOG84 has 
been made in the presence of histological confirmation of extracardiac sarcoidosis 
combined with imaging and/or clinical findings of CS and the exclusion of other 
cardiac diseases. In contrast to the recommendation of the HRS statement,83 EMB 
has been the preferred first biopsy procedure even in the presence of extracardiac 
involvement. Failing that, either an imaging-guided repeat EMB or extracardiac 
biopsy, depending on the details of the individual case, has been the next step. In 
selected cases of suspected serious isolated CS and negative EMBs, the diagnosis 
has been pursued by open-chest myocardial biopsy.119,236,237 The flowchart in Figure 
7 represents an overview of the diagnostic practice in our institution.
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Figure 7. Diagnostic flowchart of suspected cardiac sarcoidosis at Helsinki University Hospital. 
CMRI: cardiac magnetic resonance imaging; EMB indicates endomyocardial biopsy; LGE: late 
gadolinium enhancement; MC: myocardial; MLn: mediastinal lymph node; 18F-FDG-PET: 18F-
fluorodeoxyglucose positron emission tomography 
Figure 7. Diagnostic flowchart of suspected cardiac sarcoidosis at Helsinki University Hospital. 
CMRI: cardiac magnetic resonance imaging; EMB indicates endomyocardial biopsy; LGE: late gadolinium 
enha ce ent; MC: myocardial; MLn: mediastinal lymph no e; 18F-FDG-PET: 18F-fluorodeoxyglucose 
positron emission tomography
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2.7 Diagnostics of giant cell myocarditis
The diagnosis requires a myocardial sample showing histology compatible with 
GCM. Typically echocardiography shows a non-dilated LV with systolic dysfunction 
ranging from mild to extremely severe, depending on the stage of disease.238–240 
Other abnormalities seen include ventricular aneurysms and wall thickness 
abnormalities, especially local hypertrophy possibly due to inflammatory cell 
infiltrate and edema.6,60,241,242 None of these findings are, however, specific or 
sensitive to GCM and rarely echocardiography can be normal or show only mild 
nonspecific findings at first presentation.239,243 Data on CMRI in GCM is limited. 
Based on a few case reports, LGE can be seen in multiple myocardial areas and 
different myocardial layers in a non-coronary distribution.243–246 In addition to 
widespread LGE, other CMRI findings include segmental hypokinesis, perfusion 
defects on first-pass perfusion imaging, high intensity signals representing edema 
on T2-weighted images, and diffusely impaired LV longitudinal strain.245,246 In 
one case report,245 areas of LGE on CMRI represented areas with GCM-specific 
histology at autopsy, while nonspecific inflammatory infiltrate was observed in 
areas exhibiting no LGE on CMRI. Published data on 18F-FDG PET in GCM is 
even more limited. The resolution of 18F-FDG PET uptake combined with clinical 
improvement can be seen in serial 18F-FDG PET studies following successful 
immunosuppressive therapy.247 Although cardiac biomarkers such as NT-proBNP 
and hs-cTnT/I levels are usually elevated in GCM, normal values at disease 
presentation are not absolutely exclusive of GCM.6,7,248
According to the American Heart Association (AHA)/American College of 
Cardiology (ACC)/European Society of Cardiology (ESC) scientific statement, to 
exclude GCM an EMB is indicated for patients with unexplained acute HF and 
hemodynamic compromise and for patients with refractory HF of subacute onset 
in the presence of LV dilatation, especially if one or more of the following are 
present: VAs, AVB, or failure to respond to usual care within one to two weeks.249 
As there is a wide variation in the clinical manifestations, and not all patients 
present with HF, a high index of suspicion is necessary.3,6,60,238 Compared to CS, 
the diagnostic yield of EMB might be better in GCM with sensitivity up to 80–85% 
in cases with a fulminant disease course.250 
The need for mechanical circulatory support is not uncommon in suspected 
GCM, and procuring myocardium for microscopy at ventricular assist device 
implantation is useful as larger and transmural samples can be studied.4,6,250–253 
Escher et al.254 identified a distinctive gene expression profile specific for cases 
with a histologically verified GCM. Intriguing as this finding is, its interpretation 
and repeatability remain fully open.
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2.8 Histopathological similarities and differential 
diagnostics of cardiac sarcoidosis and giant cell 
myocarditis
CS and GCM share many features in myocardial histology and their differentiation 
can sometimes be problematic, especially if sarcoidosis is confined to the 
myocardium.4,35,111,255,256 Multinucleated giant cells are present in both CS 
and GCM.4,35 Widespread, serpiginous myocardial necrosis associated with 
inflammatory cell infiltrates is typical for GCM,3,4,35,68 whereas necrosis in CS is 
often less severe or absent (Figure 8),4,35 although no specific threshold dividing 
GCM from CS exists. Okura et al.4 reported that fibrosis was more commonly 
observed in CS than in GCM, although this finding could be biased by the timing 
of patient presentation. Fibrosis is a less common finding in the acute phase, 
compared to more advanced stages of the disease.35 Eosinophils can be seen both 
in CS and GCM, although widespread eosinophilia is more common in GCM.3,4,68 
It is hypothesized that the cytotoxic substances of eosinophils could play a role 
in the typically extensive myocardial destruction of GCM.4 Many experts think 
that the absence of myocardial granulomas in GCM is a key factor distinguishing 
it histologically from CS.3,35,68 Differing views do, however, exist. In the landmark 
GCM study of 1997,3 Cooper et al. underlined the absence of granulomas in GCM 
but, surprisingly, a later study by the very same group did not consider granulomas 
exclusive of GCM.4 Cooper and Elamm have later specified that, in their view, 
poorly formed granulomas may be present in GCM but organized follicular 




Figure 8. Histopathological characteristics of cardiac sarcoidosis (CS) and giant cell myocarditis 
(GCM) 
Panel A demonstrates diffuse, serpiginous inflammatory infiltrate typical for GCM. In contrast 
panel B shows the well-demarcated inflammatory areas usually seen in CS. Black arrows point 
out the inflammatory infiltrates; epithelioid cell granulomas are also present at the foci 
identified by the black arrows in panel B. Panel C shows typical GCM histology with strands of 
surviving myocytes amongst diffuse myocardial damage (asterisk). Areas of abundant 
eosinophilia (red arrow) are also a hallmark of GCM. Panel D shows the granulomatous 
inflammatory infiltrates of CS. The blue arrows point out giant cells (in panels B-D) and the blue 
circle in panel D encompasses a large non-caseating epithelioid cell granuloma. The 
magnification coefficient was 100x (objective 10x, ocular tube 10x) in panels A and B and 200x 
(objective 20x, ocular tube 10x) in panels C and D. 
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In view of this, the differentiation betw e  (definite) CS and GCM must be based 
on a full scrutiny of myoc rdial samples and needs to take into account all of the 
afor mentioned histological char cteristics (see Table 5). As GCM is considered 
a myocardial disease, the detection of granulomas outside the heart should favor 
the diagnosis of CS. The presence of extracardiac granulomas should be suspected, 
for example, when hot mediastinal lymph nodes on 18F-FDG PET are present 
or findings consistent with pulmonary sarcoidosis are seen on CT. However, 
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several reports describing typical GCM histology on myocardial biopsy with 
proven extracardiac sarcoidosis exist,68,258,259 further complicating the differential 
diagnosis. Lastly, myocardial gene expression profiling has been proposed to 
differentiate between GCM and CS.111
Table 5. Histopathological differences between GCM and CS
GCM CS
Granulomas Absent* Mandatory for diagnosis
Necrosis +++ +




Pattern of inflammation Diffuse inflammatory infiltrates Sharply delineated inflammation
*Disagreement among experts whether the presence of granulomas is absolutely exclusive of 
GCM; see text (section 2.8) for details
+, ++, and +++ indicate the amount of a given feature on histopathological examination as mild, 
moderate, and severe, respectively
CS indicates cardiac sarcoidosis; GCM: giant cell myocarditis
2.9 Therapy
2.9.1 Background and general principles
The elements of the management of CS consist of immunosuppressive therapy, 
treatment of HF and VAs, and the prevention of SCD. Inhibition of inflammation 
by immunosuppressive therapy aims to preserve myocardial function. The drugs, 
devices, and interventional therapies used to treat HF and VAs in general260–264 
apply also for CS. Some CS-specific recommendations for the management of 
VAs and the prevention of SCD exist as well.80,83,260,261 The risk stratification and 
prevention of SCD by implanting an implantable cardioverter defibrillator (ICD) 
constitute pivotal steps in the management of CS. A major problem is the total 
lack of prospective and controlled treatment trials. The practice of care therefore 
varies between institutions and is heavily dependent on local experience. The 
existing treatment recommendations80,83,265 are based on the consensus of experts 
interpreting data from mainly small and retrospective observational studies.
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2.9.2 Immunosuppressive therapy in cardiac sarcoidosis
Corticosteroids are the mainstay of immunosuppressive therapy in CS. The 
premise justifying corticosteroid use in sarcoidosis is based on the assumption 
that by inhibiting inflammatory granuloma formation and subsequent long-
term fibrosis, organ function is preserved.266 HF in CS is a result of widespread 
myocardial fibrosis,14,91,267 but lesser degrees of fibrosis can still act as a substrate 
for life-threatening VAs.22,174,176 The optimal dosage and duration of corticosteroid 
therapy in CS is still unclear. One retrospective trial showed no difference in 
survival between patients receiving initial high (≥40 mg) vs. low (< 30mg) dose 
prednisone.8 Many authors suggest follow-up 18F-FDG PET imaging for monitoring 
treatment response and tailoring immunosuppressive therapy.24,86,223 Up until now 
there is, however, limited evidence to support that this improves treatment results. 
A prospective clinical trial is ongoing to address some of the unanswered issues 
of immunosuppressive therapy in CS.268 
Typically, prednisolone is started at a dose of 20–60 mg daily and gradually 
tapered to a maintenance of 5 to 10 mg daily.8,269–271 In a meta-analysis of 10 studies 
totaling 257 CS patients receiving corticosteroids, treatment duration varied from 
three to 168 months.270 After discontinuation of corticosteroids, close follow up for 
relapses is recommended.270 Some authors advise against stopping corticosteroids 
altogether,272 while others suggest corticosteroid-sparing immunosuppressive 
therapy for long-term management.273 In a retrospective single-center study from 
2015, Nagai et al. found no benefit in terms of cardiac survival for 67 CS patients 
treated with corticosteroids vs. 16 patients not receiving corticosteroids for various 
reasons.144 However, LVEF improved 7.9% and worsened 16.7% in patients receiving 
vs. not receiving steroids, respectively. Also, fewer HF hospitalizations were seen 
in patients receiving corticosteroid therapy. Data from retrospective small to 
medium-sized studies suggest that corticosteroid therapy might be associated with 
LV function maintenance or improvement in CS.9,144,270,272,274 Sadek et al. outlined 
data on the association of corticosteroid therapy with LV function from four 
studies totaling 79 CS patients.270 They concluded that corticosteroid therapy was 
associated with maintenance of normal LVEF or improvement in LVEF in patients 
with mild to moderate LV dysfunction, but no improvement was seen in patients 
with severely depressed LVEF at baseline. In 2016, Nagai et al. published a report 
comparing 49 CS patients receiving long-term corticosteroid therapy and 12 CS 
patients in whom steroid therapy was discontinued due to improvement of clinical 
condition.272 Patients with discontinuation of prednisolone had a significantly 
greater percentage decrease in LVEF than those with continuation of therapy (% 
change in LVEF: −23.1 ± 11.9% vs +5.9 ± 5.4%, p = 0.037). Padala et al. reported 
that in a study of 30 CS patients, 14 had depressed LVEF at presentation, and that 
early initiation of corticosteroids in 9/14 patients resulted in an improvement of 
45
mean LVEF (25% to 46%, P < 0.001) compared to no improvement in five of the 
14 patients with delayed initiation of treatment.274 
Evidence from small cohorts suggests that AV conduction can recover 
after initiation of corticosteroid therapy, especially when initiated early in the 
inflammatory phase.272,274–276 Apart from prednisolone, no consensus exists on 
the use of other immunomodulatory drugs in CS. According a Delphi study 
in the United States,277 most commonly used non-corticosteroid drugs were 
methotrexate, azathioprine, mycophenolate mofetil, and infliximab, an anti-
TNF agent. Infliximab has been used as a second- or third-line drug for patients 
with persistent inflammation and/or side-effects from corticosteroid or other 
immunomodulatory drugs.278–280 Based on small and retrospective case series, 
initiating infliximab may help reduce the dose of steroids with maintained or 
improved cardiac function, fewer VAs, and reduced inflammation on 18F-FDG 
PET.278–280 Side effects include thrombo-embolic, infectious, and allergic 
complications.278–280 An earlier report suggested that infliximab may worsen HF 
in non-CS patients with depressed LVEF,281 but this was not observed in the later 
reports focusing on infliximab use in CS.278–280
2.9.3 Immunosuppressive therapy in giant cell myocarditis
In their landmark study of GCM published in 1997, Cooper et al.3 reported that in 
the 33 patients receiving immunosuppressive therapy, corticosteroids were used 
either alone or in various combinations with cyclosporine, azathioprine, and/or 
murine monoclonal T cell antibody (muromonab-CD3). The use of combination 
immunosuppression resulted in a better median survival compared to patients 
not receiving immunosuppression (12.3 months vs 3.0 months; p=0.001). 
Corticosteroids alone appeared not to improve survival. In 2008, a prospective 
randomized study was launched by the same group,5 but only 11 patients could 
be recruited over a six-year period. All patients received a cyclosporine-based 
immunosuppressive therapy. Muromonab-CD3 was given to all but two patients. 
Corticosteroids were given intravenously for three days and then converted to oral 
prednisolone therapy. Without a placebo-arm, a benefit in terms of survival could 
not be concluded but serial EMBs revealed that after four weeks of treatment, the 
degree of necrosis, cellular inflammation, and giant cells decreased.5 The scheme for 
immunosuppressive therapy in GCM in Helsinki University Hospital is described 
in detail in our earlier report.6 In short, a triple combination of cyclosporine, 
prednisone, and azathioprine is the recommended treatment. Exceptionally, 
other immunosuppressive drugs, like mycophenolate mofetil, methotrexate, or 
the anti T-cell agent muromonab-CD3, have been added or substituted for the 
above agents. The target for maintenance cyclosporine concentrations has been 
in the lower range for immunosuppression after cardiac transplantation. It is 
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recommended to continue a small prednisone dose along with cyclosporine for 
prolonged periods.     
There are some reports of encouraging results from the use of tacrolimus282 
and anti T-cell agents other than muromonab-CD325,283 in GCM. A recent expert 
consensus document on the management of acute myocarditis recommends anti 
T-cell agents together with high-dose intravenous steroids for fulminant GCM.265
2.9.4 Management of heart failure
Pharmacological therapy of heart failure with reduced ejection fraction in CS and 
GCM should be implemented according to the published guidelines on HF.262–264 
As in cardiomyopathies caused by other etiologies, ACE inhibitors and beta-
blockers should be administered with the addition of a mineralocorticoid receptor 
antagonist to patients who remain symptomatic. In the 2016-published ESC and 
2017-published ACC HF guidelines,262,264 sacubitril/valsartan is recommended 
instead of ACE inhibitor for patients who remain symptomatic despite optimal 
ACE inhibitor, beta-blocker, and mineralocorticoid receptor antagonist therapy. 
In a 2021-published ACC expert consensus decision pathway for the optimization 
of HF treatment, direct initiation of sacubitril/valsartan is preferred to patients 
naive for ACE-inhibitors/angiotensin receptor blockers.284 With limited disease-
specific data, general recommendations regarding cardiac resynchronization 
therapy apply for GCM and CS.262,263,285,286
2.9.5 Transplantation in cardiac sarcoidosis and giant cell myocarditis
For eligible patients, cardiac transplantation is a worthy option for terminal HF or 
intractable recurrent VAs defying all other therapies. In CS, several studies report 
favorable long-term survival rates after cardiac transplantation. A retrospective 
analysis of transplantation outcomes from 38 US transplant centers spanning 
an 18-year time period reported a five-year overall survival of 80% in all 86 
transplanted CS patients.287 The authors observed a better one-year post-transplant 
survival in CS compared to other indications in a total of 38,165 contemporaneous 
patients.287 Recurrence of CS in the allograft has been reported, sometimes even 
after several years post transplantation.140,288 
In GCM, drug-and device therapy-resistant progressive HF and/or incessant 
VAs may necessitate cardiac transplantation. In their landmark study, Cooper et 
al.3 reported that 34 of the 63 patients collected worldwide underwent cardiac 
transplantation. A report of 32 GCM patients from the United Network for Organ 
Sharing (UNOS) registry showed a post-transplant survival comparable to survival 
in DCM or other types of myocarditis despite higher rates of acute rejection in 
GCM.289 Disease recurrence in the allograft is reported in 10–43% of cases of 
GCM,3,6,112,290 and is often asymptomatic.3,112 
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In some cases, the use of mechanical circulatory support is necessary as a 
bridge to either recovery or transplantation. According to the UNOS registry, 
pre-transplantation support was necessary in more than half of GCM patients.289 
Another study concluded that of 41 GCM patients requiring mechanical circulatory 
support, 24 (58.5%) ultimately received cardiac transplantation.253 In CS patients 
undergoing cardiac transplantation, mechanical circulatory support as a bridge 
to transplantation is necessary in a quarter of all patients.291,292
2.9.6 Management of ventricular arrhythmias
For the most part, the AHA/ACC/HRS and ESC general guidelines on management 
of VAs are applicable to patients with CS and GCM.260,261 They also contain some 
CS- and GCM-specific recommendations. In addition, the JCS and HRS have 
published detailed recommendations for the management of VAs in CS.80,87 The 
emergence of new data is reflected in the evolution of guidelines. For example, 
by giving more in-depth recommendations, the 2017-published AHA/ACC/HRS 
guidelines on the management of VAs superseded the 2008 ACC/AHA/HRS 
Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities where 
it was briefly stated that ICD implantation is reasonable (IIa, level of evidence C) 
for patients with CS and GCM with no further specifications. The indications for 
ICD therapy in CS and GCM are discussed separately in section 2.13.
2.9.6.1 Anti-arrhythmic drugs and immunosuppressive pharmacotherapy
The role of immunosuppressive therapy in the treatment of VAs in CS is 
controversial.144,177,270,272,293–296 Some studies report a reduction of VAs and a risk 
of cardiac death,24,177,272,294,295 while others do not.144 A study by Yogodawa et al. 
suggests that corticosteroid therapy could be beneficial in reducing VAs in the 
early stages of CS when LV function is still preserved.294 
In another single-center study of 18 CS patients with VAs, a good antiarrhythmic 
response to immunosuppression and anti-arrhythmic drugs (AAD) was reported in 
patients with proven inflammatory activity on 18F-FDG PET, while RFCA provided 
good results in patients without signs of active inflammation.24 The 2014-published 
HRS expert consensus statement on the diagnosis and management of arrhythmias 
in CS, the 2017 JCS Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis 
and the 2017-published AHA/ACC/HRS guidelines for the management of patients 
with VA state that immunosuppressive medication can be useful in reducing VAs in 
CS.80,83,260 It is however acknowledged that the data supporting this is limited.83,260 
In GCM, incidental case studies have reported conflicting results of 
immunosuppressive therapy in reduction of VAs.20,25,26,185,246,297,298 Resolution 
of inflammation by immunosuppression in the acute setting might prove 
successful in controlling the incessant VAs that are presumably associated with 
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inflammation,25,26,185,298 whereas the monomorphic VTs seen later probably relate 
to myocardial scarring.20,246
There are no randomized trials on AADs in CS or GCM. In addition to beta-
blockers, amiodarone is commonly used for the control of VAs in CS.24,177 Class 
I AADs increase mortality in patients with previous myocardial infarction299,300 
and could have a similar adverse interaction with myocardial scarring due to 
CS or GCM as well. The HRS expert consensus statement advises against 
using class I AADs in CS.83 In contrast, the JCS allows class I AADs for the 
management of uncontrollable VAs.80 Incessant VAs can pose a major therapeutic 
challenge and impair the prognosis of patients with CS and GCM. In addition 
to AADs, augmentation of immunosuppression, or initiation of a combination 
immunosuppressive pharmacotherapy in newly diagnosed GCM, might be useful 
in controlling incessant VAs if there is evidence of ongoing inflammation.23–26,83,298 
2.9.6.2 Radiofrequency catheter ablation of ventricular tachycardia
RFCA has been used for drug-refractory VAs in CS.18,19,23,24,175–179,301–303 Several 
studies report encouraging results in VT suppression post-ablation, even though VT 
recurrences are common.18,19,24,175–177,179 VAs are less frequent and more controllable 
by AADs post-ablation. In 2015, Kumar et al.176 reported a one-year VT-free 
survival of only 37% after multiple RFCAs in 21 CS patients. Still, VT control 
was achieved in most of the patients with fewer AADs. In 2018 Papageorgiou et al. 
published a systematic review in which they identified 83 CS patients across five 
studies undergoing RFCA.179 VT recurrence was observed in 54.2% of patients but 
88.4% of patients were deemed to benefit from RFCA in terms of total freedom 
from VT or a reduction of VT burden. For GCM, data on RFCA is very limited 
and consists of solitary case reports.20,26,297 It should probably be considered as 
a bail-out option but as the arrhythmic substrate is usually extensive, complete 
control of all VT circuits can be challenging. 
The AHA/ACC/HRS or ESC guidelines for management of VAs do not give 
specific recommendations for RFCA in CS or GCM.260,261 Some evidence exists 
that RFCA can control incessant VAs in both CS and GCM.20,175,297 According to 
the HRS expert consensus statement, RFCA can be useful in CS patients suffering 
from incessant VAs and VAs refractory to immunosuppression and AADs.83 Major 
complications include access site vascular complications, hemopericardium/
cardiac tamponade and thromboembolic events.304 In their systematic review, 
Papageorgiou et al. reported a complication rate of 4.7–6.3% in RFCA procedures 
in CS.179 This is comparable to the reported complications rates of VT RFCA 
procedures in general.304 In anecdotal cases, sympathetic denervation for VAs, 
unresponsive to AADs and RFCA, have shown favorable results.305
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2.10 Long-term outcome 
It should be noted that several factors complicate the interpretation of reported 
outcome data in CS and GCM. Survival figures depend on the analyzed outcome 
(e.g., overall survival, cardiac survival, transplant-free survival) and on whether 
the study included patients diagnosed only at autopsy. Study populations are 
usually relatively small, and composite endpoints are common. These endpoints 
typically consist, in addition to the “hard” endpoints mentioned above, of less 
severe events such as VT, development of AVB, or hospitalization for HF. As 
practically all prognostic studies are retrospective, some events may be less reliable 
than others and susceptible to subjective interpretation (e.g., hospitalization for 
HF). Also, in CS, the diagnostic criteria (JMHW/JCS guidelines,80,82 HRS expert 
consensus statement,83 WASOG criteria84 or other institutional definition) vary 
between studies. In addition, some prognostic data has been derived from study 
populations comprising both confirmed and suspected cases of CS.
2.10.1 Overall and transplantation-free survival in cardiac sarcoidosis
Two retrospective studies from the early 21st century4,8 and two more recent 
studies9,108 report on overall- and transplant-free survival in CS. Yazaki et al.8 
studied 95 CS patients and reported an overall five-year survival of 75% in the 75 
patients diagnosed during life and receiving corticosteroids. Okura et al.4 studied 
and compared 42 CS patients (all with histological verification from myocardial 
biopsy) and 73 GCM patients and reported a five-year transplant-free survival of 
60.5% in CS. In the 29 biopsy-diagnosed CS patients, survival was 69.8% at five 
years. Later, in 2015, Kandolin et al.9 reported survival data from 110 consecutive 
CS patients in Finland (also a subgroup of the patient population presented in 
this thesis). The overall transplantation-free cardiac survival at five years was 
as high as 90% in all 110 patients. In the 102 patients diagnosed during life, the 
corresponding figure was 95%.9 In 2017, Zhou et al.108 reported that in 73 patients 
with probable or highly probable CS, transplant-free survival was as good as 96% 
at five years. Almost all (71 of 73 patients) received immunomodulatory treatment. 




































































































































































































































































































































































































































































































































































































































































































2.10.2 Transplantation-free survival in giant cell myocarditis
In their study of 63 GCM patients by Cooper et al.,3 the median transplant-
free survival was only 5.5 months from symptom onset. However, as many as 
25 (40%) of patients were diagnosed only at autopsy or from explanted hearts, 
likely biasing the overall survival figures. The median transplant-free survival for 
patients receiving immunosuppressive therapy was 12.6 months. The expanded 
GCM series of the same group4 showed a transplant-free survival of only 10% 
at five years in 73 GCM patients, which differed markedly from the outcome in 
CS (see above). Of note, an ICD was implanted in only 12% and 24% of GCM 
and CS patients, respectively. In 2015 Maleszewski et al.13 reported on 26 GCM 
patients surviving without transplantation for more than one year post-diagnosis. 
All patients received immunosuppressive therapy and an ICD was implanted in 
65% of patients. The transplant-free survival at five years was 72%. Although 
better survival might be explained by advances in HF therapy and a higher rate 
of ICD implantations, a major survivorship bias is more than likely as patients 
dying within the first year of their diagnosis were excluded from the study. Table 
7 shows studies reporting outcome in GCM.
Table 7. Studies reporting transplantation-free survival in GCM





Okura et al. 20034 73 - 10%
Five-year transplant-free 
survival was 21.9% in 
patients diagnosed from 
EMB
Cooper et al. 20085 11 73% -





Maleszewski et al. 201513 26 - 72%
Study limited to GCM 
patients surviving > one 
year after diagnosis
EMB indicates endomyocardial biopsy; GCM, giant cell myocarditis
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2.10.3 Incidence of sudden cardiac death and life-threatening 
ventricular arrhythmias
2.10.3.1 Cardiac sarcoidosis
The occurrence of life-threatening arrhythmic events in CS patients is not 
uncommon in clinical practice. However, the true frequency of SCD due to CS is 
unknown, partly because CS may be completely silent until arrhythmic death, and 
these patients remain outside clinical CS registries. On the other hand, there is 
an unknown number of individuals with undiagnosed CS, surviving arrhythmia-
free in the population, also complicating the estimation of the true risk of VAs.
Kandolin et al. reported that during a median follow-up of 6.6 years, only one 
of 110 CS patients died from HF, while 10 patients suffered an SCD and another 11 
were successfully resuscitated from cardiac arrest.9 Another study from Finland 
comprising 143 consecutive CS patients with high-degree AVB (also a subgroup of 
this thesis) concluded that the estimated five-year incidence of SCD was 17% and 
the five-year estimated incidence of either SCD or VT was 31%.12 In a Japanese 
single-center study of 53 consecutive CS patients,11 a total of 21 patients (40%) had 
a VF or VT during a median follow-up of 34 months. Table 8 lists more studies 
reporting the frequency of life-threatening VAs in CS. Finally, the risk of VAs may 
be especially high in the early course of CS. Segawa et al.10 reported that 20 out 
of 68 (29%) CS patients had a VT after initiation of steroid therapy and that VT 
occurred within 12 months in 14 of the 20 patients.
Not surprisingly, appropriate ICD therapies are also common in CS (Table 9). 
Kron et al. reported on the outcomes of 235 CS patients with an ICD.16,17 During 
a mean follow-up of 4.2 years, appropriate therapies (shocks or antitachycardia 
pacing) were seen in 85 of 234 (36%) patients and the annual therapy rate was 
8.6%. Appropriate ICD therapy was seen in 33 of the 147 (22%) CS patients 
receiving an ICD for primary prevention.17 A retrospective study from three centers 
in the US with 112 CS patients with an ICD reported that nearly a third received 
appropriate therapies during a mean follow-up of 29.2 months.310 A VT storm (> 
three episodes in 24 hours) was seen in 16 (14.2%) patients. Of the 83 patients 
with a primary preventive ICD, 27.7% received appropriate therapies during follow 
up and the annualized event rate was also fairly high, at 11.3%. Appropriate ICD 
therapy is, however, not entirely synonymous with life-threatening VAs as many 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































et al. 2005311 15 Suspected CS† 47%
Not reported for 
ICD receivers 60%
Mehta  
et al. 2011306 8 HRS
83 0% Median  5.6 years 50%
Schuller  






















et al. 2017314 27 JMHW
 82 52% Median  12 years 56%
*Includes 99 patients described earlier by Betensky et al. and Schuller et al.
†Tissue biopsy or Kveim test positive extra-CS and cardiac symptoms
‡ Additional criteria included LGE on CMRI and inducible VT on PVS
§ Extra-CS + fulfilled the JMHW criteria and/or had positive CMRI or 18F-FDG PET or direct 
myocardial confirmation of sarcoidosis
**(i) biopsy-proven CS, (ii) CMRI findings suggestive of CS, or (iii) biopsy-proven sarcoidosis 
in another organ and presumptive cardiac involvement based on conduction system disease 
involving the sinus node, AV node, or His-Purkinje system and/or VAs.
AV indicates atrioventricular; CS: cardiac sarcoidosis; HRS: Heart Rhythm Society; ICD: 
implantable cardioverter defibrillator; JMHW: Japanese Ministry of Health and Welfare. 
2.10.3.2 Giant cell myocarditis
Compared to CS, much less data exist on the incidence of VAs in GCM. The reports 
of the Multicenter GCM Study Group3,4 showed that a ventricular tachyarrhythmia 
was the second most common presenting manifestation and developed in almost 
half of cases during the disease course. The study of one-year GCM survivors 
by Maleszewski et al. showed that six of 26 patients (23%) had VTs both at 
presentation and during a mean follow-up of 5.5 years.13 
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2.11 Prognostic factors in cardiac sarcoidosis
2.11.1 Clinical characteristics and biomarkers
Aside from one study reporting poorer outcomes in older patients,108 age has not 
been associated with overall or transplant-free survival in CS.4,8,9 The severity of 
HF symptoms (New York Heart Association functional class (NYHA)) predicted 
mortality in the study by Yazaki et al.8 and transplant-free survival in the study 
by Kandolin et al.9 Yazaki et al. also reported that sustained VT predicted worse 
overall survival.8 Zhou et al. found that patients who received an ICD or pacemaker 
had a better transplant-free survival, but the authors speculated that the more 
favorable prognosis might have been related to a closer cardiac follow-up rather 
than to the device per se.108
Kron et al. reported that appropriate ICD therapies were associated, in addition 
to lower LVEF, with male sex, history of syncope, ventricular pacing at baseline 
ECG, and a secondary preventive indication for an ICD (p< 0.05 in all).16 In a 
later study of the same population, the authors also concluded that patients with 
isolated CS had high rates of appropriate ICD therapies (69.2% vs 33.8% in patients 
with cardiac and extracardiac sarcoidosis; p=0.015).17 Of note, isolated CS was also 
associated with a composite end-point of cardiac survival free of transplantation 
and aborted SCD in the report by Kandolin et al.9 Two studies describe the 
arrhythmic risk of CS patients presenting with AVB.11,12 Nordenswan et al. reported 
that the rate of SCD in CS patients with AVB and LVEF > 50% was 9% at five 
years,12 and Takaya et al. reported that the rate of cardiac survival free of VF or VT 
was similar between CS patients with AVB and CS patients with previous VT and/
or HF11. A recent meta-analysis315 reported that in patients who had appropriate 
ICD therapy, high-degree AVB was more frequent (p=0.05). Interestingly, ICD 
indication (primary vs. secondary preventive), age, or LV function did not differ 
between the group who had appropriate ICD therapy vs. the rest.
Limited data on the prognostic role of cardiac biomarkers in CS exist.196,201 Kiko 
et al.201 reported on 49 CS patients and concluded that, in a multivariate model 
accounting for LVEF with 11 fatal arrhythmias as endpoint events, higher cTnI 
values at baseline were predictive of adverse outcomes with a hazard ratio (HR) of 
2.348 (95%CI 1.272–4.333). In the work by Nordenswan et al.,7 cTnT/I levels were 
independently associated with a composite endpoint of fatal or aborted cardiac 
death or transplantation after adjusting for CS vs. GCM diagnosis, LVEF, and BNP 
level. BNP levels were predictive of outcome in a univariate analysis but lost their 
significance when adjusted for the aforementioned parameters.
In summary, earlier VAs and a history of syncope predict increased risk of 
future life-threatening VAs in CS. Additional risk factors include presentation with 
AVB, isolated CS, higher NYHA functional class, and having either ventricular-
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paced rhythm or high circulating concentrations of cardiac troponin or BNP at 
the onset of follow-up. The data regarding age and sex as risk factors is somewhat 
conflicting. 
2.11.2 Ventricular function
Several studies have linked impaired LV function with worse overall and 
transplant-free survival in CS.8,9,108 It has also been consistently associated with 
varying composite adverse endpoints including, in addition to mortality and 
transplantation, HF hospitalization, life-threatening VAs, and development of 
AVB.27,30,316 Of note, ventricular aneurysms, present in 8–40% of CS cases,14,135 
are also linked to adverse cardiac events135 and can usually be readily detected by 
echocardiography. Basal thinning of the interventricular septum in CS patients, 
not an uncommon morphological finding, has also been associated with future 
adverse cardiovascular events.317 Severely reduced LV function (LVEF < 35%) is a 
well-recognized risk indicator for future life-threatening VAs in cardiomyopathies 
in general.260,261 CS does not make an exception to this,10,12,16,27,310 but perhaps due 
to concomitant active inflammation and progressive scarring, many patients 
with near-normal to normal LVEF may still be at significant risk of later 
VAs.11,12,16,27,29,312,315 Table 10 lists studies reporting on the association of LVEF and 
life-threatening VAs in CS. In the study by Rosenthal et al.,29 49 of 110 CS patients 
(44.5%) had a VA or SCD over a median follow-up of 2.6 years. Importantly, a 
significant proportion (38.5%) of the 78 patients in the subgroup with LVEF ≥35% 
also had an arrhythmic endpoint. Also, after adjustment for age, presence of CAD 
or chronic kidney disease, LVEF of < 35% did not predict VAs or SCD.29 In a recent 
meta-analysis on the role of ICDs in CS, no difference in LVEF was seen in patients 
having vs. not having appropriate ICD therapies.315 Kron et al.16 and Betensky et 
al.312 have also shown that a major proportion of appropriate ICD therapies in CS 
occurs in patients with LVEF > 35%. Chiba et al. found a significantly better VT/
VF-free survival in 56 CS patients with LVEF > 50% compared to 35 patients 
with LVEF < 50% but, still, seven (13%) out of the 56 patients with LVEF > 50% 
experienced a VT or a VF during a mean follow-up of 84 months.27 Nordenswan et 
al.12 reported that CS patients with AVB and prior VT or LVEF < 35% had a higher 
risk of fatal or life-threatening VAs than individuals with AVB and LVEF 35–50%. 
However, even in the subgroup of lone AVB comprising patients with LVEF> 50% 
and no history of VTs, the estimated five-year incidence estimate of SCD or VT 
was as high as 24%. Lastly, besides LVEF, RV ejection fraction (RVEF) has also 
been associated with adverse outcomes.28,212,310 In conclusion, although depressed 
LVEF is a robust overall risk indicator in CS, many patients with near-normal to 
normal LV function still have a high risk of life-threatening VA.
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Table 10. Studies evaluating the association of LVEF and risk of life-threatening VAs in CS
Study Patients CS criteria Follow-up Results
Kron  
et al. 201316




The mean LVEF for patients 
who received appropriate 
ICD therapies was lower 
compared with those who 




22 CS patients with 
high-degree† AVB JMHW 2006
82 median  
34 months
LVEF < 50% was not 
predictive of cardiac death, 
VT, or VF
Segawa  
et al. 201610 68 CS patients JMHW 1993
81 mean  
5.5 years
LVEF was a predictor for 




143 CS patients with 
high-degree† AVB HRS
83 median  
2.8 years
LVEF was associated with 
SCD or VT (SHR 1.39; 95%CI 
1.03–1.86)
Chiba  
et al. 202027 91 CS patients JMHW 2006
82 mean  
84 months
VT/VF-free survival was 
better in patients with LVEF 
≥ 50%
Rosenthal  
et al. 202029 110 CS patients HRS
83 median  
2.6 years
Patients with LVEF < 35% 
had greater occurrence of 
sustained VT/VF/SCD
*Based on the MIDFIN registry and represents an overlapping patient population with the one 
presented in this thesis
†Mobizt II second- or third-degree AVB
‡(i) biopsy-proven cardiac sarcoid, (ii) magnetic resonance imaging (MRI) findings suggestive 
of cardiac sarcoid, or (iii) biopsy-proven sarcoidosis in another organ and presumptive cardiac 
involvement based on conduction system disease involving the sinus node, AV node, or His-
Purkinje system and/or ventricular arrhythmias.
AVB indicates atrioventricular block; CS: cardiac sarcoidosis; HR: hazard ratio; ICD: implantable 
cardioverter defibrillator; LVEF: left ventricular ejection fraction; PM: pacemaker; SCD: sudden 
cardiac death; SHR: subdistribution hazard ratio; VA: ventricular arrhythmia; VF: ventricular 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.11.3 Advanced cardiac imaging 
2.11.3.1 Cardiac magnetic resonance imaging
CMRI is the most accurate method for assessing ventricular function, the well-
known but, as mentioned above, insensitive predictor of adverse events. Most 
studies have focused on other, potentially more accurate CMRI parameters (see 
Table 11). There are multiple studies reporting that the presence (vs. absence)93,307,316 
or quantity of LGE28,30 is associated with adverse events in known or suspected 
CS, and that LGE clearly outweighs LVEF as an outcome predictor. For example, 
Murtagh et al.28 studied 205 sarcoidosis patients and concluded that increased 
LGE burden combined with RV dysfunction identified patients with the highest 
risk of death and/or VT. It should be noted that only a fifth of these patients 
probably had true CS, as only 20% of cases exhibited LGE on CMRI.28 Several 
other studies have likewise analyzed populations consisting of patients with extra-
cardiac sarcoidosis having suspected CS or undergoing routine CMRI screening 
for cardiac involvement (Table 11). In these studies, the prognostic significance of 
LGE is most probably explained by the fact that pathological LGE identifies the 
true CS subpopulation. 
2.11.3.2 18F-fluorodeoxyglucose positron emission tomography
In recent years, several studies, summarized in Table 12, have studied the 
prognostic role of 18F-FDG PET in CS. In a study by Blankstein et al., the presence 
of focal perfusion defects with abnormal 18F-FDG uptake was associated with a 
significantly higher risk of death or VT.182 Another study of 203 patients with 
suspected CS showed that the heterogeneity of metabolism on 18F-FDG PET 
(quantified using the coefficient of variation of 18F-FDG uptake), and the summed 
score of abnormal perfusion and 18F-FDG uptake in different myocardial segments 
were predictive of death, transplantation, or VT.323 In contrast, in the study by 
Bravo et al., 18F-FDG PET offered no additive prognostic information on top of 
LGE CMRI.322 
2.11.4 Programmed ventricular stimulation
Aizer et al.311 reported that in 32 patients with sarcoidosis and suspected cardiac 
involvement, inducible VAs were associated with future ICD therapies or SCD (HR 
4.47, 95%CI 1.30 to 15.39). Inducible VAs were also predictive of future arrhythmic 
events in the 26 patients without previous spontaneous VTs (HR 6.97, 95%CI 1.27 
to 38.27). The mean LVEF was < 35% in both PVS-positive and PVS-negative 
group. Also, two (10%) patients without previous spontaneous or inducible VAs 
still had sustained VAs or SCD during follow-up. In another study101 with 19 CS 
patients undergoing PVS, six out of eight patients with positive PVS had a later VT 
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or VF. The median LVEF in this group was 38%. The median LVEF in the PVS-
negative group was significantly higher, at 61%. One of the 11 (9%) PVS-negative 
patients had a sustained VT during follow-up, suggesting a negative predictive 
value of PVS for an arrhythmic event of 91%. Mehta et al.306 studied the usefulness 
of PVS in risk stratification in 76 CS patients without a history of spontaneous 
VAs. During a median follow-up of five years, six out of eight (75%) patients in the 
PVS positive group had an arrhythmic event or died compared to one death from 
respiratory failure in the PVS negative group (p < 0.0001). It is noteworthy that 
the mean baseline LVEF was 36.4±4.2 in the PVS positive group and 55.8±1.5 in 
the PVS negative group. Thus, the additional benefit of PVS in risk stratification in 
this cohort, after estimation of LV function, remains unclear. Another study of 25 
patients with probable or definite CS and abnormal myocardial LGE or 18F-FDG 
uptake, reported a 100% positive predictive value for positive PVS.324 One of 10 
patients with LVEF > 35% and no prior VAs had a VA during follow-up.
In conclusion, inducible VAs by PVS during an invasive electrophysiological 
study are associated with the occurrence of future clinical VAs in CS. It is 
however somewhat unknown if PVS provides additive prognostic value over LVEF 
estimation. Even more importantly, it is unclear if a baseline negative PVS can be 
relied upon to omit ICD implantation.101,306,311,324
2.12 Prognostic factors in giant cell myocarditis
Aside from the works of the present thesis, no other studies specific to the 
predictors of outcome in GCM exist.
2.13 Implantable cardioverter defibrillator indications in 
cardiac sarcoidosis and giant cell myocarditis
An ICD can be considered to improve prognosis in selected patients with CS 
or GCM by preventing an arrhythmic SCD. Evidence from controlled studies 
is lacking, however, and the decisions to implant, for primary prevention in 
particular, are not straightforward. The benefits of ICD are mitigated by the 
risk of device complications,325 including inappropriate shocks,16,310,312 and by 
ICD’s psychological effects.326 Overall, roughly one fifth of CS patients receive 
inappropriate ICD shocks,327 with the annual risk, attributable mainly to 
supraventricular arrhythmias, being 4.1–5.7%.16,310,312 In GCM, there is little data 
specific to the therapeutic role of ICD implantations.3,6,13 As fatal or aborted SCDs 
are not uncommon,7 implantation appears worthy of consideration if the disease 
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course is not fulminant and prospects for survival without urgent transplantation 
are favorable. Table 13 summarizes the current ICD indications in CS by the HRS 
2014 and the AHA/ACC/HRS 2017 recommendations. The main difference is the 
inclusion of the presence of myocardial scar on CMRI or PET as a Class IIa ICD 
indication in the 2017 consortium guidelines. Another significant difference is 
that the consortium guideline does not require a trial of immunosuppression 
prior to implantation in patients with an LVEF ≤  35%, a view shared by other 
experts.328 The JCS has published national recommendations for the use of ICD 
in Japan, which are clearly more restrictive and are not dealt with in detail here.80 
There is little experience of wearable cardioverter defibrillators in CS or GCM.329 
Such a device might, however, be useful as a bridge to transplantation,330 in cases 
with a delay in obtaining definitive diagnosis,331 and in patients with a temporary 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3 AIMS OF THE STUDY
The initial focus of this thesis was to study the incidence and risk factors of life-
threatening VAs and the risk of SCD in CS and GCM. During the work, several 
cases of CS mistaken for GCM were detected and an additional aim was set to 
study the relationship and differential diagnostics of CS and GCM.
Specifically, the aims were:
- To study the occurrence of SCD both as the first presenting manifestation and 
as the mode of death in CS (IV) and GCM.
- To analyze the incidence of life-threatening VAs and their predictors in CS (I) 
and GCM (III).
- To evaluate survival in CS (IV) and GCM (II)
- To investigate the reasons for mistaking CS for GCM and to compare the 
characteristics, survival, and incidence of life-threatening VAs in “true” GCM 
vs CS initially mistaken for GCM (V, IIb, IIIb).
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4 STUDY COHORTS, MATERIALS, AND METHODS
4.1 MIDFIN registry
The MIDFIN study group is a cardiology research network of Finland’s five 
university hospitals focusing on CS and GCM. Since 2008, it has maintained 
a regularly updated nationwide registry of CS and GCM patients seen in the 
university hospitals and in provincial hospitals providing tertiary cardiac care. 
This web-based registry is accessible from the participating hospitals by a two-
step authentication process. It includes patients diagnosed from the late 1980s 
onwards with data on their demographics, symptoms, clinical manifestations, 
results of diagnostic imaging and laboratory studies, invasive procedures, 
details of treatment, and adverse events including mortality and cause of death 
determined by hospital chart review. Specifically, the collected imaging data 
included echocardiographic LVEF as well as information on the presence of 
18F-FDG uptake on PET and LGE on CMRI. Laboratory studies collected included 
the results of cTnT/I and NT-proBNP measurements. The assigned cardiologists 
and/or research assistants from the participating hospitals regularly update the 
registry for incident cases and for data from the routine clinical follow-up visits of 
prevalent cases. The registry was founded in 2008 and collection of data from 1988 
up to 2008 was therefore fully retrospective. All cases diagnosed as CS, presenting 
from 1998 through 2015, and cases initially diagnosed as GCM, presenting from 
1991 through 2015, were included in this thesis. Five CS cases included in the 
MIDFIN registry prior to 1998 were omitted from the present work to ensure 
temporal parallelism with data from the cause-of-death registry (see section 4.2 
below).
4.2 Cause-of-death registry
In Finland, a death certificate stating the main cause of death is issued for every 
deceased person. A medicolegal investigation into the cause of death is mandatory 
by law in all cases where the deceased has not been under the care of a physician 
during their last illness, death is not due to a known disease, or is otherwise 
unexpected or non-natural. Text bodies of the death certificates from the national 
cause-of-death registry are available in digital format from 1998 onwards. To detect 
cases of CS and GCM escaping a lifetime diagnosis, we searched the database 
for cases where the primary cause of death was documented with the ICD-10 
code D86.8+I41.8 (CS) as well as for cases where the cause of death was coded 
as D86 (sarcoidosis), I51.4 (myocarditis, unspecified), or I40 (acute myocarditis) 
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and either the phrases “cardiac sarcoidosis” or “giant cell myocarditis” were 
present in the text body of the death certificate. The registry search covered the 
timespan from 1998 through 2015. We excluded cases that were already included 
in the MIDFIN registry at the time of the database search, as well as cases where 
histological material could not be acquired for re-examination. For the remaining 
cases, all histological material available from autopsies was re-examined. The 
written autopsy reports were scrutinized for observations of other cardiac diseases 
and extracardiac organ involvement of sarcoidosis.
4.3 Diagnostic criteria
4.3.1 Cardiac sarcoidosis
For CS, we adhered to the diagnostic criteria advocated in the HRS expert 
consensus statement83 as well as in the WASOG diagnostic instrument for 
CS.84 The diagnosis of CS required documentation of sarcoidosis histology in a 
sample of myocardium (the preference), or in extracardiac tissue, combined with 
clinical cardiac manifestations and abnormalities in cardiac imaging. Findings 
indicative of cardiac involvement on echocardiography included ventricular wall 
abnormalities and depressed LVEF. Typical CMRI findings included patchy LGE 
patterns not conforming with coronary artery distribution and local ventricular 
wall abnormalities. Typical 18F-FDG PET findings included focal myocardial 
18F-FDG uptake with or without perfusion defects. The histological criteria for 
sarcoidosis were the presence of non-necrotizing epithelioid cell granulomas with 
giant cells and no more than solitary eosinophils without extensive myocardial 
necrosis. 
4.3.2 Giant cell myocarditis
For studies II and III, the diagnosis of GCM required myocardial histology showing 
myocyte injury with or without necrosis associated with multinucleated giant cells 
and an inflammatory infiltrate variably composed of lymphocytes, histiocytes, 
and eosinophils. The presence of well-formed granulomas excluded the diagnosis 
of GCM. The available diagnostic myocardial samples for patients in studies II 
and III were verified by two cardiac pathologists applying the criteria above. In 
two cases, the original samples were unavailable for reanalysis. One of the two 
diagnoses was based on autopsy and the other on EMB. The available histology 
reports described findings typical for GCM by experienced pathologists and both 
cases were retained in studies II and III.
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For the later re-evaluation of GCM diagnoses (see sections 4.4 and 5.1), the 
histological criteria for GCM were identical to the ones used previously for studies 
II and III with the exception that the presence of any myocardial granulomas 
recognizable with reasonable certainty, including the immature ones identified 
with the help of immunohistochemistry, were considered diagnostic of CS and 
exclusive of GCM. Furthermore, cases where extracardiac histology confirmed 
or 18F-FDG PET strongly suggested the presence of systemic sarcoidosis were 
reclassified from GCM to CS, even in the absence of myocardial granulomas. 
4.3.3 Grading of myocardial injury (studies II and III) 
Two cardiac pathologists re-analyzed in retrospect all material available from 
the diagnostic myocardial biopsies of patients included in original studies II and 
III. The extent of cardiomyocyte necrosis and the number of eosinophils were 
graded visually on hematoxylin-eosin–stained samples using a semiquantitative 
four-point scale (0, 1, 2, and 3 for none, mild, moderate, and severe, respectively). 
The extent of myocardial fibrosis was scored in a similar manner on slices stained 
with Masson’s trichrome. All scores were based on the pathologists’ consensus. 




Figure 9. Grading of the extent of myocardial necrosis (left panels) and fibrosis (right panels). 
Myocardial necrosis was graded from hematoxylin- and eosin-stained slices. Panel N1 
represents mild, N2 moderate, and N3 severe myocardial necrosis, respectively. Gradually less 
normal myocytes (black arrows) with an increasing amount of necrosis (asterisk) are seen from 
panel N1 through N3. The grading of fibrosis was based on Masson’s trichrome-stained 
histological samples showing fibrosis in blue. Examples of mild (F1), moderate (F2), and severe 
(F3) myocardial fibrosis are shown. The scores given for necrosis and fibrosis were a result of 
the consensus of two cardiac pathologists, based on visual estimation. The original 
magnification coefficient is 100x (objective 10x, ocular tube 10x) in panels F1–F3 and 200x 












Figure 9. Grading of the extent of myocardial necrosis (left panels) and fibrosis (right panels). Myocardial 
necrosis was graded from hematoxylin- and eosin-stained slices. Panel N1 represents mild, N2 moderate, 
and N3 severe myocardial necrosis, respecti ly. Gradually less normal myocytes (black arrows) with 
an increasing amount of necrosis (asterisk) are seen from panel N1 through N3. The grading of fibrosis 
was based on Masson’s trichrome-stained histological samples showing fibrosis in blue. Examples of 
mild (F1), moderate (F2), and severe (F3) myocardial fibrosis are shown. The scores given for necrosis 
and fibrosis were a result of the consensus of two cardiac pathologists, based on visual estimation. 
The original magnification coefficient is 100x (objective 10x, ocular tube 10x) in panels F1–F3 and 200x 
(objective 20x, ocular tube 10x) in panels N1–N3.
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4.4 Re-evaluation of giant cell myocarditis diagnoses
In 2018, while working on Study IV, we came across several cases of CS that had 
initially been mistaken for GCM. As it was apparent that this problem could also 
involve the GCM populations of our earlier works (studies II and III), we decided 
to re-evaluate each GCM diagnosis made during the period covered by the present 
thesis. For the review of the GCM cases from the MIDFIN registry, we acquired all 
histologic material still available from the original diagnostic myocardial biopsies 
as well as any specimens available from follow-up myocardial biopsies, explanted 
or autopsied hearts, or extracardiac tissues. In addition to microscopy, we also 
used other information pertinent to the differentiation of CS from GCM, including 
imaging studies with either 18F-FDG PET or plain chest CT. The acquisition of 
review material for cases from the cause-of-death registry is described above in 
section 4.2. The histopathological re-evaluation of all GCM cases was made by 
two examiners having > 10 years of experience in cardiovascular pathology. Their 
consensus was needed to convert the diagnosis of GCM to CS in clinicopathological 
meetings with the cardiologists involved in studies II and III.  
4.5 Study population
This thesis included 351 cases of CS with disease presentation in Finland from 
1998 through 2015 and 29 cases of GCM presenting from 1991 through 2015.
4.5.1 Cohorts in studies I–V
- Study I: all CS patients seen in Helsinki University Hospital from Feb 2004 
through 2014 with sufficient quality CMRI studies and absence of CAD (n=59). 
These patients also constitute a subgroup of Study IV.
- Study II: all cases with an initial diagnosis of GCM seen in Helsinki University 
Hospital from 1991 through May 2015 (n=46). 
- Study III: the 46 patients of Study II with five additional cases diagnosed until 
January 2016. 
- Study IV: 351 adult (> 18 years) CS cases presenting from 1998 through the end 
of 2015. Of them, 263 cases were identified from the MIDFIN registry and 61 
from the cause-of-death registry; the remaining 27 were initially misdiagnosed 
as GCM in the MIDFIN registry and later reclassified as CS (see sections 4.4 
and 5.1).
- Study V: 73 adult (> 18 years) patients with a diagnosis of GCM at the start of 
our re-evaluation study in 2018. Of these, 49 came from the MIDFIN registry 
and 24 from the cause-of-death registry.  
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4.6 Data collection
For studies I–III and V, I reviewed the pertinent hospital charts for patients’ 
symptoms, initial and later disease manifestations, diagnostic laboratory and 
imaging examinations, treatment and its complications, and occurrence of adverse 
events up to the end of 2015. For Study IV, I collected the above information from 
the database of the MIDFIN registry and from the autopsy reports and hospital 
charts of CS patients diagnosed only at autopsy. 
The collected laboratory data included measurements of cTnT and NT-proBNP 
taken and analyzed as part of clinical routine. The collected imaging data included 
LVEF by echocardiography, presence of 18F-FDG uptake on PET and of LGE on 
CMRI, as well as findings of coronary angiography. The CMRI studies of patients 
in Study I were re-analyzed in detail for the purposes of the present research 
(see section 4.7). For patients in studies II and III, I scrutinized the available ICD 
reports and collected the details of appropriate and inappropriate ICD therapies. 
In study V, data from studies II and III were used with the addition of details 
collected from the autopsy reports and hospital charts pertinent to the GCM cases 
diagnosed postmortem. The histological material was reanalyzed as described 
above. I determined the causes of death from hospital charts and/or from autopsy 
reports. The data collection was mainly retrospective and took place between 
2013 and 2018.
4.7 Analysis of cardiac magnetic resonance imaging studies
Analysis was performed using dedicated software (QMass MR 7.60.30.0; Medis). 
LV and RV volumes and LV mass were derived by manually drawing LV endo- 
and epicardial contours and RV endocardial contours on all short-axis slices from 
base to apex at end-diastole and end-systole. Papillary muscles and endocardial 
trabeculations were regarded as part of the ventricular cavity. LV wall thickness 
was calculated and the presence of marked basal septal thinning (< 4mm) was 
separately noted. Separate regions of interest representing healthy myocardium 
free of LGE and myocardium with intense LGE were drawn on a slice optimally 
distinguishing healthy from diseased heart muscle. The extent of LGE as a 
percentage of LV mass was then automatically calculated using the full width 
at half maximum method333 for defining the threshold for LGE (Figure 10). The 
presence of edema was analyzed from T2-weighted images. Edema was defined 
as myocardial signal intensity > 1.9-fold the intensity in the skeletal muscle and 
classified as either present or absent. I personally analyzed all CMRI studies. To 
assess the repeatability of image analysis, an independent expert and I later blindly 
re-analyzed 10 randomly selected studies. The Bland-Altman method was used to 




Figure 10. Examples of mild (panels A and B) and extensive (panels C and D) late gadolinium 
enhancement (LGE) on cardiac magnetic resonance imaging (CMRI).  
Panels A and C show selected mid-ventricular LGE-CMRI short-axis slices with mid-myocardial 
LGE. Panels B and D are the same slices with LGE semi-automatically quantified and painted in 
red. The global LGE extent (percentage of LV volume) by the full-width half-maximum method 
(see methods section 4.7) was 8% and 27% in the patients with representative images shown in 
panels A/B and C/D, respectively. 
 
4.8 Definitions of study endpoints  
The outcome endpoint for Study I was a composite of death from cardiac cause, transplantation, 
or life-threatening VA, whichever came first. Life-threatening VA was defined as (1) SCD; (2) 
aborted SCD, that is, VF defibrillated successfully either by an ICD or externally during 
resuscitation; or (3) VT requiring ICD therapy or synchronized external cardioversion or 
defibrillation. The endpoint for studies II and V was a composite of death or cardiac 
transplantation. For Study III, the primary endpoint event was SCD (fatal or aborted), and the 
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4.8 Definitions of study endpoints 
The outcome endpoint for Study I was a composite of death from cardiac cause, 
transplantation, or life-threatening VA, whichever came first. Life-threatening VA 
was defined as (1) SCD; (2) aborted SCD, that is, VF defibrillated succ ssfully either
by an ICD or externally during resuscitation; or (3) VT requiring ICD ther py or 
synchronized external cardioversion or defibrillation. The endpoint for studies 
II and V was a composite of death or cardiac transplantation. For Study III, the 
primary endpoint event was SCD (fatal or aborted), and the secondary endpoint 
event was a composite of SCD or any life-threatening VA. In Study IV, the endpoint 
event was death from any cause. Considering the information available to us of 
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the circumstances of death, the fatal event was classified as SCD if the witnessed 
prodromal symptoms had lasted < 24 hours (instead of the < 1 hour definition) 
and the victim arrested and died immediately at the scene or was primarily 
successfully resuscitated from cardiac arrest but died later without neurological 
recovery. An unwitnessed death was considered SCD if CS or GCM was the only 
cardiac pathology at autopsy and the available medical history together with 
autopsy findings and other medicolegal studies (including toxicology) excluded 
other causes of death. 
4.9 Ethical aspects
The MIDFIN registry study gained the approval of the national ethical review 
board from 2009 (STM/1219/2009). The study of fatalities in CS and GCM 
was approved by the ethical review board in 2015 (317/13/03/01/2015). Two 
Finnish governmental authorities, the National Authority for Medicolegal 
Affairs (4615/06.01.03.01/2016) and the National Institute for Health and 
Welfare (THL/691/5.05.00/2016) approved the study of cases from the cause-
of-death registry and the review of postmortem autopsy material. The studies 
were conducted according to the Declaration of Helsinki. The patients gave their 
informed, written consent to data collection for the national MIDFIN registry.
4.10 Statistical analyses
Continuous variables are presented as mean value ± standard deviation when 
sample distribution was symmetric, and median (minimum – maximum or 
interquartile range) when sample distribution was skewed. Categorical variables 
are presented as absolute numbers and percentages. The Pearson r was calculated 
when testing for linear correlation between two continuous variables. Comparisons 
between groups were performed using x2 statistics for categorial variables and 
Student’s t-test or Mann-Whitney U test for continuous variables, as appropriate. 
In all tests, a two-tailed p < 0.05 was considered statistically significant. 
The time point of GCM diagnosis was defined as the date of myocardial 
biopsy confirming the diagnosis of GCM. Survival time was calculated from the 
date of onset of symptoms compatible with CS or GCM (studies II–V) or from 
the date of CMRI study (Study I). Survival curves were plotted and survival 
estimates were calculated by the Kaplan-Meier method. Cause-specific cumulative 
incidence analysis was used to plot the incidence–time curves. Between-group 
comparisons were made by the log rank test for the Kaplan-Meier method and 
by the Gray test for the cumulative incidence analysis. HRs and subdistribution 
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HRs were calculated by Cox regression analysis and by the Fine and Gray model, 
respectively. In cumulative incidence analysis and the Fine and Gray model, 
cardiac transplantations and deaths caused by terminal HF were considered 
competing events. The validity of proportional hazards assumption was tested 
by calculating Schoenfeld (partial) residuals and plotting them against follow-up 
time. The assumption was considered valid if no statistically significant time-
dependent correlation was observed. The analyses were performed using SPSS 
versions 22.0–24.00 for Macintosh (SPSS Inc.; Chicago, IL, USA), Xlstat Biomed 
(Addinsoft, Paris, France) and R software (R Development Core Team).
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5 RESULTS
5.1 Re-evaluation of giant cell myocarditis diagnoses 
At the end of 2015, the MIDFIN registry included 51 cases of GCM collected 
from 1991 onwards. These patients constituted the population of Study III, and 
46 of them (until May 2015) constituted the population of Study II. After the full 
re-evaluation work, the diagnosis was converted to CS in as many as 27/51 (53%) 
instances, the reasons being as follows. In 20 cases originally missed myocardial 
granulomas were found, varying from occasional well-formed follicular structures 
to granulomas in different earlier stages of development (Figure 11). In one case 
transplanted in 2018, abundant granulomas had been noted in the routine 
clinical explant study and the diagnosis was converted to CS. In two more cases 
transplanted for GCM, re-evaluation of specimens available from the native hearts 
revealed granulomas that had been missed in the original explant study. In one 
further post-transplant case, follow-up allograft biopsies showed a recurrence 
of disease with granulomas diagnostic of CS escaping recognition in routine 
clinical practice. Immature myocardial granulomas had been detected during 
original diagnostic work-up in one case but the initially assigned diagnosis was 
still GCM. In one case, sarcoid granulomas were found on the microscopy of renal 
tissue and finally, in one case with poor-quality original myocardial specimens, 
18F-FDG PET-CT taken at presentation showed extracardiac inflammatory activity 
(mediastinal lymph nodes and lungs) favoring the diagnosis of CS. 
Screening of the cause-of-death registry exposed 24 cases of GCM diagnosed 
at autopsy by forensic (n=21) or general (n=3) pathologists until the end of 2015. 
After the re-evaluation, a total of 19 of these cases (79%) were reclassified as CS. 
In nine of them, myocardial granulomas had been missed in the initial autopsy 
study (Figure 12), while in 10 cases, either extra-cardiac or cardiac granulomas had 
been detected but the assigned diagnosis was still GCM. The most common sites 
for the extracardiac granulomas were mediastinal lymph nodes, lungs, kidneys, 
and liver (Figure 13). 
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Figure 11. Detection of immature granulomas.  
Hematoxylin eosin-stained myocardial tissue shows dense lymphocytic infiltrate with paler 
areas (black asterisk) representing immature granulomas (A). Immunohistochemical staining for 
markers of CD68 (B), PD-L1 (C), and CD4 (D) highlight the granulomas (white asterisk). The 
magnification coefficient is 100x (objective 10x, ocular tube 10x) in all microphotographs. 
 
 
Taken together, more than half (46/75, 61%) of all cases diagnosed initially as GCM during the 
study period were reclassified as CS. The results of the original analyses, done before the re-
evaluation and reclassification of cases, are reported in the original articles (studies II and III) 
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Figure 12. Autolysis complicating the recognition of myocardial granulomas.  
In a post-mortem myocardial sample, tissue autolysis causes giant cells to lose nuclei (black 
arrows) and granulomas (asterisk) become less evident. The original magnification coefficient is 
400x (objective 40x, ocular tube 10x). 
5.2 Characteristics of the study population 
5.2.1 Cardiac sarcoidosis 
A total of 351 incident cases of CS, 253 females and 98 males, with a mean age of 52±12 years, 
were included in the study. Figure 14 shows their temporal distribution over the study period 
and Table 14 summarizes their key characteristics at the time of disease presentation. The 
diagnosis was absolute (i.e., based on myocardial histology) in 221 cases (63%), being made 
from lifetime diagnostic biopsies in 149 cases, at autopsy in 62 cases, and at the post-transplant 
study of the native heart in 10 cases. In the remaining 130 cases, sarcoid histology was 
confirmed from biopsies of lymph nodes or solid organs in 104 and 26 cases, respectively. At 
presentation, extra-cardiac sarcoidosis was detected in 98 patients. Subsequent investigations 
during follow-up revealed extra-cardiac involvement in 127 additional patients. Patients with a 
lifetime diagnosis of CS (n=289) were younger at the time of presentation compared to patients 
diagnosed only at autopsy (50±10 vs. 57±16; p=0.004). A trend toward more females in the 
lifetime-diagnosis group was observed (74% vs 65%; p=0.059). Of all 351 CS patients, 237 were 
screened for CAD either by invasive or CT coronary angiography, or at autopsy. Significant CAD, 
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Figure 12. Autolysis complicating the recognition of myocardial granulomas. 
In a post-mortem myocardial sample, tissue autolysis causes giant cells to lose nuclei (black arrows) 
and granulomas (asterisk) become less evident. The original magnification coefficient is 400x (objective 
40x, ocular tube 10x).
5.2 Characteristics of the study population
5.2.1 Cardiac sarcoid sis
A total of 351 incident cas s of CS, 253 f male  nd 98 ales, with a mean age of 
52±12 ye rs, were included in the stud . Figure 14 hows their temporal distribution
over the study period and Table 14 umm rizes their key characteristics at the 
time of disease pres ntation. The diag osis was absolute (i.e., based on myocardial 
h stology) in 221 ca es (63%), being made from lifetime diagnostic biop ies in 
149 cases at autopsy in 62 cases, and at the post-transplant study of the ative 
heart in 10 cases. In the emaining 130 cases, sarcoid hist logy was confirmed 
from biopsies f lymph nodes or s lid org ns in 104 and 26 cases, respectively. At 
presentation, extra-cardiac sarcoidosis was detected in 98 patients. Subs quent 
inv stigati n  during f llow-up revealed extra-cardiac involvement in 1 7 
additional pati nts. Patient  with a lifetime diagnosis of CS (n=289) were younger 
at the time of presentation compared to patients diagnosed only at autopsy (50±10 
vs. 57±16; p=0.004). A trend toward more females in the lifetime-diagnosis group 
was observed (74% vs 65%; p=0.059). Of all 351 CS patients, 237 were screened 
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for CAD either by invasive or CT coronary angiography, or at autopsy. Significant 
CAD, defined as more than 50% stenosis in the left main stem, proximal left 
anterior descending branch or in at least 2 main epicardial arteries, was present 
in eight cases, five of which were detected at autopsy. 
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defined as more than 50% stenosis in the left main stem, proximal left anterior descending 
branch or in at least 2 main epicardial arteries, was present in eight cases, five of which were 
detected at autopsy.  
 
 
Figure 13. Conversion of the diagnosis from GCM to CS based on study of extracardiac tissue.  
Endomyocardial biopsy (A), demonstrated wide myonecrosis (asterisk), with few preserved 
myocytes (arrowhead), giant cells (thin arrow) and eosinophilia, suggesting a diagnosis of GCM. 
However, microscopy of lung biopsy showed distinct non-caseating, well-formed epithelioid 
granulomas (thick arrow) diagnostic of sarcoidosis (panel B). The original magnification 
coefficient is 200x (objective 20x, ocular tube 10x) in both panels. 
 
As Table 14 shows, high-degree AVB was the most common presenting manifestation (42%) 
followed by HF (17%). SCD without preceding symptoms, fatal or aborted, was the first and only 
manifestation in 14% of all CS cases. Of the 38 patients presenting with fatal SCD, 29 died at 
home. Sixteen of these SCDs were witnessed, seven were associated with physical exertion, and 
autopsy revealed concomitant severe CAD in four cases.  
 
A total of 24 patients with a post-mortem diagnosis of CS had presented with lifetime symptoms 
attributable to CS in retrospect. Each of them had undergone diagnostic studies, outlined in 
Table 15, but escaped lifetime diagnosis. Their median survival from onset of symptoms was 1.2 







Figure 13. Conversion of the diagnosis from GCM to CS based on study of extracardiac tissue. 
Endomyocardial biopsy (A), demonstrated wide myonecrosis (asterisk), with few preserved myocytes 
(arr whead), giant cells (thin arrow) and eosinophilia, suggesting a diagnosis of GCM. How ver, 
microscopy of lung biopsy showed distinct non-caseating, well-formed epithelioid granulomas (thick 
arrow) diagnostic of sarcoidosis (panel B). The original magnification coefficient is 200x (objective 
20x, ocular tube 10x) in both panels.
As Table 14 shows, high-degree AVB was the most common presenting 
manifestation (42%) followed by HF (17%). SCD without preceding symptoms, 
fatal or aborted, was the first and only manifestation in 14% of all CS cases. 
Of the 38 patients presenting with fatal SCD, 29 died at home. Sixteen of these 
SCDs were witnessed, seven were associated with physical exertion, and autopsy 
revealed concomitant severe CAD in four cases. 
A total of 24 patients with a post-m rtem diagnosis of CS had presented with 
lifetime symptoms attributable t  CS in retrospect. Each of hem had undergo e 
diagnostic studies, outlined in Table 15, but escaped lifetime diagnosis. Their 
median survival from onset of symptoms was 1.2 years (range 0.1–11.7).
A B
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Table 14. Characteristics of the CS Population at Presentation
All cases
N=351
Age (at presentation) 52±12
Female 253 (72)
Presenting manifestation
AVB (third degree or Mobitz II second degree) 147 (42)
LV dysfunction with heart failure 58 (17)
Sudden cardiac death 50 (14)
Fatal 38 (11)
Aborted 12 (3)
Sustained VT 48 (14)
Frequent ventricular extrasystoles 20 (6)
Syndrome mimicking myocardial infarction* 11 (3)
Exertional chest pain 3 (1)
Atrial tachyarrhythmia 4 (1)
Non-specific symptoms† 10 (3)
Imaging studies
LV ejection fraction ≤ 50% 174/305 (57)
LV ejection fraction < 35% 51/305 (17)
LGE-CMRI 181 (52)
Abnormal myocardial LGE 171 (94)
18F-FDG PET-CT 191
Abnormal cardiac 18F-FDG uptake 165 (86)
Cardiac troponin T > 50 ng/L 51/244 (21)
Cardiac troponin T > 500 ng/L 12/244 (5)




Severe CAD at angiography or autopsy‡ 8 (2)
Severe renal failure (GFR < 30 mL/min/1.732) 4 (1)
Cancer 31 (10)
Data relates to number (%) of cases, medians (interquartile range), or mean ± standard deviation 
*chest pain, ischemic ECG and normal coronary angiogram
†one or more of the following: unexplained syncope, elevated cardiac troponin, fatigue, dyspnea, 
or bundle-branch block on the electrocardiogram.
‡, defined as more than 50% stenosis in at least two main epicardial arteries, in the proximal left 
anterior descending branch, or in the left main stem
AVB indicates atrioventricular block; CAD: coronary artery disease; COPD: chronic obstructive 
pulmonary disease; CS: cardiac sarcoidosis; GFR: glomerular filtration rate; LGE-CMRI: late 
gadolinium enhancement cardiac magnetic resonance imaging; LV: left ventricular; NT-
proBNP: N-terminal pro b-type natriuretic peptide; VT: ventricular tachycardia; 18F-FDG PET-CT: 
18F-fluorodeoxyglucose positron emission tomography-computed tomography
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Figure 14. Temporal distribution of new cases of cardiac sarcoidosis (CS) from 1998 to the end 
of 2015 
 
Table 15. Characteristics and diagnostic examinations of the 24 symptomatic CS patients escaping a 
lifetime diagnosis 
  N=24 
Age (at presentation) 57±13 
Female 16(67) 
Presenting manifestation  
AVB third degree or Mobitz II second degree 13(54) 
Left ventricular dysfunction with heart failure 7(29) 
Exertional chest pain 3(13) 
Unexplained syncope 1(4) 
Diagnostic studies  
Echocardiography 17 (LVEF < 50% in 11) 
Coronary angiography 10 (all with normal findings) 
LGE-CMRI 1 (widespread myocardial LGE) 
18F-FDG PET-CT 
1 (myocardial perfusion defect 
without 18F-FDG uptake) 
Endomyocardial biopsy 2 (both non-diagnostic) 
Data relates to number (%) of cases or mean±SD   
AVB indicates atrioventricular block; CS: cardiac sarcoidosis; LGE-CMRI: late gadolinium enhancement 
cardiac magnetic resonance imaging; LVEF: left ventricular ejection fraction; 18F-FDG PET-CT: 18F-


























Figure 14. Temporal distribution of new cases of cardiac sarcoidosis (CS) from 1998 to the end of 2015
Table 15. Characteristics and diagnostic examinations of the 24 symptomatic CS patients escaping a 
lif time diagnosis
N=24
Age (at presentation) 57±13
Female 16(67)
Presenting manif station
AVB third degree or Mobitz II second degree 13(54)
Left ventricular dysfunction with heart failure 7(29)
Exertional chest pain 3(13)
Unexplained syncope 1(4)
Diagnostic studies
Echocardiography 17 (LVEF < 50% in 11)
Coronary angiography 10 (all with no m l findings)
LGE-CMRI 1 (widespread myocardial LGE)
18F-FDG PET-CT 1 (myocardial perfusion defect  without 18F-FDG uptake)
Endomyocardial biopsy 2 (both non-diagnostic)
Data relates to number (%) of cases or mean±SD 
AVB indicates atrioventricular block; CS: cardiac sarcoidosis; LGE-CMRI: late gadolinium 
enhancement cardiac magnetic resonance imaging; LVEF: left ventricular ejection fraction; 
18F-FDG PET-CT: 18F-fluorodeoxyglucose positron emission tomography-computed tomography
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5.2.2 Giant cell myocarditis
Altogether, 29 cases of GCM were included in the study, 20 females and nine 
males, with a mean age at presentation of 57±13 years. Figure 15 shows their 
temporal distribution over the study period and Table 16 presents their key 
characteristics at the time of presentation. The samples of myocardium for the 
study of histology had been obtained by EMB in 20 cases, at cardiac surgery in two 
cases, at the post-transplant study of the native heart in one case, and at autopsy 
in six cases. On reanalysis of the myocardial histology in the 21 GCM patients with 
material available from diagnostic lifetime biopsies, 10 patients (48%) had grade 
2–3 (moderate to severe) myocyte necrosis and two patients (10%) had grade 2–3 
myocardial fibrosis. Grade 2–3 myocardial necrosis and fibrosis did not overlap, 
and thus either of these findings was present in 12 (57%) patients. The number 
of eosinophils on biopsy material was graded 2–3 in 12 (57%) patients. None of 
the 29 patients had significant CAD.
A lifetime diagnosis was made in 22 (76%) patients with a median time from 
symptom onset to diagnosis of 0.3 months (range 0–4.6 months). HF was the most 
common presenting manifestation (45%) followed by AVB (21%) and SCD (14%). 
Three (50%) of the six patients with an autopsy diagnosis of GCM had presented 
with lifetime symptoms attributable to GCM in retrospect. Each of them had 
undergone diagnostic studies but escaped a lifetime diagnosis. 
5.3 Treatment in brief
5.3.1 Cardiac sarcoidosis
Altogether, 276 of 313 CS patients presenting with lifetime symptoms received 
immunosuppressive therapy consisting of various combinations of corticosteroids 
(n=274), azathioprine (n=114), mycophenolate mofetil (n=20), cyclosporine (n=22), 
methotrexate (n=18), and infliximab (n=7). An ICD was implanted in 189 patients, 
and 77 patients received a permanent pacemaker. A total of 27 patients underwent 
cardiac transplantation, and RFCA of VT was done in 15 patients.  
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5.3.2 Giant cell myocarditis
Of 26 patients presenting with lifetime symptoms, 21 (81%) received 
immunosuppressive therapy. This consisted of corticosteroid monotherapy in 
seven patients and a combination of prednisolone, azathioprine, and cyclosporin 
in 14 patients. An ICD was implanted in 13 patients and a permanent pacemaker in 
six patients. Of the 13 patients with an ICD, 10 (77%) and three (23%) individuals 
received the device for primary and secondary prevention, respectively. Beta-
blockers were used in 22 patients (85%), amiodarone in 14 patients (54%), and 
mexiletine in two (8%). RFCA of VT was done in three patients. An LV assist 
device was implanted in two patients and extracorporeal membrane oxygenator 
was used in three cases. Twelve patients underwent cardiac transplantation.
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AVB third degree or Mobitz II second degree 6 (21)
LV dysfunction with heart failure 13 (45)
Sudden cardiac death 4 (14)
Fatal 3 (10)
Aborted 1 (3)
Sustained VT 3 (10)
Other* 3 (10)
Imaging studies
LV ejection fraction < 35% 8/25 (32)
LV ejection fraction ≤ 50% 19/25 (76)
LGE-CMRI 12 (41)
Abnormal LGE 12 (100)
18F-FDG PET-CT 2(7)
Abnormal 18F-FDG uptake 2 (100)
Cardiac troponin T > 50 ng/l 18/20 (90)
Cardiac troponin T > 500 ng/l 16/20 (80)
NT-proBNP (ng/L) 5495 (2835–12309)
Associated diseases
Other autoimmune disorders† 4(14)
Diabetes 2(7)
Severe CAD at angiography or autopsy‡ 0
Severe renal failure (GFR < 30) 0
Cancer 1(3)
Data relates to number (%) of cases, medians (interquartile range), or means ± standard 
deviation
*syndrome mimicking myocardial infarction (n=1), elevated cardiac troponin, fatigue (n=1), and 
frequent ventricular premature beats (n=1).
†rheumatoid arthritis, hypo- or hyperthyroidism, celiac disease, Sjogren’s syndrome, iritis, or 
ulcerative colitis 
‡ defined as more than 50% stenosis in at least two main epicardial arteries, in the proximal left 
anterior descending branch, or in the left main stem
AVB indicates atrioventricular block; CAD: coronary artery disease; CMRI: cardiac magnetic 
resonance imaging; GCM: giant cell myocarditis; GFR: glomerular filtration rate; LGE: late 
gadolinium enhancement; LV: left ventricular; NT-proBNP: N-terminal pro b-type natriuretic 





Figure 15. Temporal distribution of new cases of giant cell myocarditis (CGM) from 1991 to the 
end of 2015 
 
5.4 Aspects of outcome in cardiac sarcoidosis and giant cell myocarditis 
5.4.1 Modes of death and survival in cardiac sarcoidosis 
Table 17. Modes of death in all 84 cases of fatal CS                                                           
Mode of death All cases (N=84) 
Sudden cardiac death 67(80) 
Autopsy diagnosis, CS only 54(64) 
Autopsy diagnosis, CS and CAD 5(6) 
Lifetime diagnosis, CS only 7(8) 
Lifetime diagnosis, CS and CAD 1(1) 
Death due to heart failure 6(7) 
Non-cardiac death 6(7) 
Cancer 5(6) 
Miliary tuberculosis 1(1) 
Death post cardiac transplantation 5(6) 
Acute rejection 1(1) 
Chronic rejection 1(1) 
Intracerebral bleeding 1(1) 
Cancer 1(1) 
Sepsis 1(1) 
Data are number (%) of cases   
CAD indicates coronary artery disease; CS, cardiac sarcoidosis  
Figure 15. Temporal distribution of new cases of giant cell myocarditis (CGM) from 1991 to the end of 2015
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5.4 Aspects of outcome in cardiac sarcoidosis and  
giant cell myocarditis
5.4.1 Modes of death and survival in cardiac sarcoidosis
Table 17. Modes of death in all 84 cases of fatal CS
Mode of death All cases (N=84)
Sudden cardiac death 67(80)
Autopsy diagnosis, CS only 54(64)
Autopsy diagnosis, CS and CAD 5(6)
Lifetime diagnosis, CS only 7(8)
Lifetime diagnosis, CS and CAD 1(1)










Data are number (%) of cases 
CAD indicates coronary artery disease; CS, cardiac sarcoidosis
Of all 351 CS patients, 84 died during the study period. Table 17 details the different 
modes of death in these patients. Of note, 67 of all 84 fatalities (80%) were SCDs. 
Of the 313 patients presenting with cardiac symptoms during life, 46 (15%) 
died. Their follow-up time from symptom onset to death or end of study was 42 
months (interquartile range 16–76 months). Only 22 deaths (26% of all) involved 
patients with a lifetime diagnosis of CS. Concomitant severe CAD was present at 
autopsy in six out of the 67 fatalities due to SCD. Table 18 shows the one-, five-, 
and 10-year Kaplan-Meier survival estimates for all CS patients presenting with 
lifetime symptoms (n=313) and separately for patients who were diagnosed with 
CS during life and received CS-targeted treatment (n=289). In the latter group, 
98% of patients were estimated to survive beyond one year, and 93% beyond five 
years, from symptom onset. 
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Table 18. Kaplan-Meier survival estimates (95% confidence intervals) for the CS population
Estimate All CS patients Patients with lifetime CS diagnosis
  N=313 N=289
One year 95% (93–98) 98% (97–100)
Five years 85% (80–90) 93% (89–96)
10 years 76% (68–84) 87% (81–94)
CS indicates cardiac sarcoidosis
5.4.2 Cardiac magnetic resonance imaging as a predictor of  
outcome in cardiac sarcoidosis 
Up until July 2014, a diagnostic CMRI study had been done in 59 CS patients 
treated at Helsinki University Hospital. For volumetric data analysis (ventricular 
volumes, wall thickness measurements, LVEF, and RVEF) we had to reject four 
cases due to insufficient image quality. For LGE analysis, nine cases had to be 
rejected, also due to insufficient quality of images. Until the end of April 2015 
a total of 23 patients had reached the study’s outcome endpoint, consisting of a 
composite of SCD (n=3), cardiac transplantation (n=1), and occurrence of life-
threatening VA (n=19; VF in 5 patients and sustained VT in 14 patients). 
CMRI variables associated with the study endpoint were RVEF (per 5% 
increment; HR 0.81, 95%CI 0.69–0.93; p=0.004), fraction of LGE from total 
LV mass (per tertiles; HR 3.06, 95%CI 1.56–6.04; p=0.001) and the presence 
of marked (< 4mm) thinning of basal interventricular septum (HR 3.64, 95%CI 
1.31–10.12; p=0.013). Contrary to RVEF, LVEF was not predictive of the endpoint 
(HR 0.90, 95%CI 0.77–1.06; p=0.202). In a multivariate Cox regression model 
including RVEF, LGE extent and presence of marked septal thinning, LGE extent 
(per tertile) was the only independent predictor of the endpoint events (HR 2.22, 
95%CI 1.07–4.59; p=0.032). The one-year estimate (95% CI) of event-free survival 
was 36% (12–60%) for patients in the highest LGE tertile (> 22% of LV mass) vs. 
80% (66–95%) in patients with less LGE (log rank p < 0.001, Figure 16). The 





Figure 16. Kaplan-Meier curves for survival free of transplantation and life-threatening 
ventricular arrhythmias for patients with the extent of myocardial late gadolinium 
enhancement (LGE) in the highest tertile (green line) vs. in the rest (blue line). 
5.4.3 Modes of death and survival in giant cell myocarditis 
By the end of 2015, 11 GCM patients had died (all of cardiac causes) and 12 had undergone 
cardiac transplantation. Eight out of the 11 deaths involved patients diagnosed with GCM during 
life. SCD accounted for five (45%) fatalities, the other modes of death being HF in three (27%) 
and death postcardiac transplantation in three (27%) cases. The follow-up time from symptom 
onset to death, transplantation, or end of study ranged from 0.1 to 133 months (median, 6 
months). Of the 12 transplantations, 10 were made because of intractable HF and two mainly 
because of VAs defying all therapies. Figure 17A shows the Kaplan-Meier graphs for both 
transplant-free and overall survival in the 26 patients presenting with lifetime symptoms. In 
these patients the one-, two- and five-year transplant-free survival estimates (95% CI) were 46% 
(26–65%), 37% (18–56%) and 26% (6–45%), respectively. The corresponding estimate of overall 
survival was 72% (54–90%), 67% (47–86%), and 67% (47–86%).  
 
Figure 16. Kaplan-Meier curves for survival free of transplantation and life-threatening ventricular 
arrhythmias for patients with the extent of myocardial late gadolinium enhancement (LGE) in the 
highest tertile (green line) vs. in the rest (blue line).
5.4.3 Modes of death and survival in giant cell myocarditis
By the end of 2015, 11 GCM patients had died (all of car iac causes) a d 12 had 
undergone cardiac transplantation. Eight out of the 11 deaths involved patients 
diagnosed with GCM during life. SCD accounted for five (45%) fatalities, the other 
modes of death being HF in three (27%) and death postcardiac transplantation 
in three (27%) cases. The follow-up time from symptom onset to death, 
transplantation, or end of study ranged from 0.1 to 133 months (median, 6 months). 
Of the 12 transplantations, 10 were made because of intractable HF and two mainly 
because of VAs defying all therapies. Figure 17A shows the Kaplan-Meier graphs 
for both transplant-free and overall survival in the 26 patients presenting with 
lifetime symptoms. In these patients the one-, two- and five-year transplant-free 
survival estimates (95% CI) were 46% (26–65%), 37% (18–56%) and 26% (6–45%), 
respectively. The corresponding estimate of overall survival was 72% (54–90%), 
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Figure 17. Panel A shows the transplantation-free (blue line) and overall (green line) survival in 
patients with giant cell myocarditis and lifetime presentation. Panel B shows the cumulative 
incidence of sudden cardiac death (SCD, blue line) and SCD or any life-threatening ventricular 
tachycardia (VT, green line) in these patients. 
5.4.4 Incidence and characteristics of life-threatening ventricular arrhythmias in giant cell 
myocarditis  
Figure 17B represents the cumulative incidences for both SCD (fatal or aborted) and SCD or any 
life-threatening VA in the 26 GCM patients presenting with lifetime symptoms. Apart from one 
late VT episode, all arrhythmic events occurred during the first year of follow-up. The 
cumulative incidence (95% CI) of either fatal or aborted SCD at one, six, and 12 months was 23% 
(11–47%), 31% (17–55%) and 41% (25–67%), respectively. The corresponding figures for SCD or 
any life-threatening VA were 23% (11–47%), 43% (27–67%) and 52% (35–76%).  
 
From among the 13 patients with an ICD, 5 (38%) had one or several appropriate ICD therapies 
during follow-up. Detailed data from 19 episodes was available for review. The arrhythmia was 
classified by the ICD as monomorphic VT on all occasions. The ventricular rate ranged from 140 
to 201 beats per minute (median, 180/min). When attempted by the ICD, antitachycardia pacing 
failed to convert VT in 6/16 (38%) episodes, of which one VT required two shocks and another 
episode required four consecutive shocks. No inappropriate shocks were observed.  
 
Amiodarone was used to prevent recurrent symptomatic episodes of VAs in 14 (54%) cases. It 
produced a complete symptomatic remission in three patients, reduced the frequency of VT 
episodes in seven patients, and had no obvious effect in four patients. RFCA or surgical ablation 
of medically uncontrollable VT was attempted in three patients. The procedures resulted in 
Figure 17. Panel A shows the transplantation-free (blue line) and overall (green line) survival in patients 
with giant cell myocarditis and lifetime presentation. Panel B shows the cumulative incidence of sudden 
cardiac death (SCD, blue line) and SCD or any life-threatening ventricular tachycardia (VT, green line) 
in these patients.
5.4.4 Incidence and characteristics of life-threatening ventricular 
arrhythmias in giant cell myocarditis 
Figure 17B represents the cumulative incidences for both SCD (fatal or aborted) and 
SCD or any life-threatening VA in the 26 GCM patients presenting with lifetime 
symptoms. Apart from one late VT episode, all arrhythmic events occurred during 
the first year of follow-up. The cumulative incidence (95% CI) of either fatal or 
aborted SCD at one, six, and 12 months was 23% (11–47%), 31% (17–55%) and 41% 
(25–67%), resp ctively. The corresponding figures for SCD or any lif -threatening 
VA were 23% (11–47%), 43% (27–67%) and 52% (35–76%). 
From among th  13 patients with an ICD, 5 (38%) had one or several app opri te 
ICD therapies during follow-u . Detailed data from 19 episodes was available for 
review. The arrhythmia was classified by the ICD as monomorphic VT on all 
occasions. The ventricular rate ranged from 140 to 201 beats per minute (median, 
180/min). When attempted by the ICD, antitachycardia pacing failed to convert 
VT in 6/16 (38%) episodes, of which one VT required two shocks and another 
episode required four consecutive shocks. No inappropriate shocks were observed. 
Amiodarone was used to prevent recurrent symptomatic episodes of VAs in 
14 (54%) cases. It produced a complete symptomatic remission in three patients, 
reduced the frequency of VT episodes in seven patients, and had no obvious effect 
in four patients. RFCA or surgical ablation of medically uncontrollable VT was 
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attempted in three patients. The procedures resulted in partial success as VT 
recurrences were abated in all patients though not abolished in any of them.
5.4.5 Factors predictive of outcome in giant cell myocarditis
Table 20 shows the results from univariate Cox regression analyses and Fine 
and Gray models of factors considered potential predictors of serious events 
in GCM. A worse transplant-free-survival was associated with the presence of 
biopsy evidence of either myocardial necrosis or fibrosis of a moderate-to-severe 
extent (p=0.013) and with elevated NT-proBNP (p=0.016). Moderate-to-severe 
myocardial fibrosis was also predictive of both fatal or aborted SCD (p=0.003) 
and any life-threatening VA (p=0.003) during follow-up. High cTnT (by tertiles) 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.5 Comparison of cardiac sarcoidosis mistaken for giant 
cell myocarditis with the ultimate giant cell myocarditis 
cohort  
5.5.1 Cases from the MIDFIN registry
The incidence of life-threatening VAs did not differ between the patients keeping 
the GCM diagnosis compared to patients reclassified as CS (Study IIIb). The 
cumulative incidence (95%CI) of life-threatening VAs at five years was 55% (28–75) 
in the 24 patients keeping the GCM diagnosis and 54% (30–73) in the 27 patients 
reclassified as CS, respectively (p=0.786). In bivariate Fine and Gray models with 
final diagnosis as the other variable, VT at presentation and moderate-to-severe 
myocardial fibrosis on microscopy were both independent predictors of life-
threatening VAs; the SHR (95% CI) was 2.87 (1.37–6.03) for the former and 6.41 
(3.17–12.94) for the latter.
5.5.2 All cases initially diagnosed as giant cell myocarditis in Finland
I compared the characteristics and survival of all 45 patients with CS initially 
diagnosed and treated as GCM with the 28 patients keeping the diagnosis of 
GCM after re-evaluation (status in 2018, study V). The GCM patients were older 
(58±10 years vs. 49±13 years, p=0.003), presented more often with HF (13/28 vs 
9/45, p=0.017) and had higher circulating levels of cTnT (median 1239 ng/L vs. 
50 ng/L, p < 0.001) and NT-proBNP (median 5273 ng/L vs. 1710 ng/L, p=0.007) 
at presentation. 
Figure 18 depicts the Kaplan-Meier transplant-free survival curves and the 
cumulative incidence curves of SCD in the 34 GCM patients reclassified as CS and 
the 25 true GCM patients, all presenting with lifetime symptoms. In the former 
group, the one- and five-year transplant-free survival estimate (95%CI) was 82% 
(70–95%) and 46% (28–64%), respectively, while the corresponding figures for 
true GCM were 45% (24–66%) and 27% (7–47%). The difference was statistically 
significant (p=0.011). In a multivariate Cox regression analysis including diagnosis, 
age, and presentation with HF as explanatory factors, final CS diagnosis was an 
independent predictor of better transplant-free survival with a HR of 0.37 (95% 
CI, 0.17–0.81; p=0.013). 
Instead, there was no statistically significant difference in the cumulative 
incidence of SCD between reclassified and true GCM (Figure 18B). 
Of the 16 CS patients initially diagnosed with and treated for GCM with 
drugs including cyclosporine, six individuals (38%) developed impaired renal 
function (glomerular filtration rate < 60 mL/min/m2) and one (6%) developed 
severe renal failure (glomerular filtration rate < 30 mL/m2/min). One (6%) patient 
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suffered from recurrent diverticulitis which was considered a complication of 
immunosuppressive therapy. No malignancies were seen in these 16 patients 
during follow up. 
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Figure 18. Comparison of transplant-free survival (A) and cumulative incidence of sudden 
cardiac death (B) between 25 patients with giant cell myocarditis (GCM, blue line) and 34 
patients with cardiac sarcoidosis (CS) initially misdiagnosed as GCM (green line) 
6 DISCUSSION 
6.1 Methodological considerations and limitations 
6.1.1 Patient population 
When the national MIDFIN registry was launched in 2008, all five university hospitals and 17 
central hospitals were contacted with a questionnaire for information on CS and GCM patients 
in their local registries. Originally, all five university hospitals and six out of 17 central hospitals 
responded. Due to the rarity of CS and GCM, many central hospitals refer these patients to 
university hospitals for diagnosis and planning of treatment. As the MIDFIN registry is hospital-
based, patients presenting with out-of-hospital SCD and diagnosed with CS at forensic autopsy 
are initially missed. In the present work, these cases were identified from the national cause-of-
death registry and included in the study population. With 351 CS and 29 GCM patients, the 
present thesis work represents one of the largest reported for both diseases. Adding the cases 
from the cause-of-death registry improved the representativeness of the cohorts although, in 
theory, it may also have introduced some reverse survivorship bias into the data. The MIDFIN 
registry mainly includes patients admitted for clinically manifest and relatively acute cardiac 
signs and symptoms. Patients with extracardiac sarcoidosis and asymptomatic or minimally 
symptomatic CS remain largely outside the MIDFIN registry and the present study. Our inclusion 
criteria adhered to the HRS consensus statement83 and WASOG diagnostic instrument84 for 
diagnosing CS, and an exceptionally large proportion of patients, nearly two thirds, had definite 
CS, i.e., the diagnosis was based on myocardial histology. The study population represents 
Figure 18. Comparison of transplant-free urvival (A) and cumulative incidence of sudden c rdiac 
death (B) between 25 patients with giant cell myocarditis (GCM, blue line) and 34 patients with cardiac 
sarcoidosis (CS) initially misdiagnosed as GCM (green line)
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6 DISCUSSION
6.1 Methodological considerations and limitations
6.1.1 Patient population
When the national MIDFIN registry was launched in 2008, all five university 
hospitals and 17 central hospitals were contacted with a questionnaire for 
information on CS and GCM patients in their local registries. Originally, all five 
university hospitals and six out of 17 central hospitals responded. Due to the 
rarity of CS and GCM, many central hospitals refer these patients to university 
hospitals for diagnosis and planning of treatment. As the MIDFIN registry is 
hospital-based, patients presenting with out-of-hospital SCD and diagnosed with 
CS at forensic autopsy are initially missed. In the present work, these cases were 
identified from the national cause-of-death registry and included in the study 
population. With 351 CS and 29 GCM patients, the present thesis work represents 
one of the largest reported for both diseases. Adding the cases from the cause-of-
death registry improved the representativeness of the cohorts although, in theory, 
it may also have introduced some reverse survivorship bias into the data. The 
MIDFIN registry mainly includes patients admitted for clinically manifest and 
relatively acute cardiac signs and symptoms. Patients with extracardiac sarcoidosis 
and asymptomatic or minimally symptomatic CS remain largely outside the 
MIDFIN registry and the present study. Our inclusion criteria adhered to the HRS 
consensus statement83 and WASOG diagnostic instrument84 for diagnosing CS, 
and an exceptionally large proportion of patients, nearly two thirds, had definite 
CS, i.e., the diagnosis was based on myocardial histology. The study population 
represents northern European ancestries only. Ethnic homogeneity is a strength 
but it can also be taken as a limitation, since it undermines the generalizability 
of our findings.
With a relatively high autopsy rate, Finland offers a good setting for cause-
of-death registry-based studies. From 1998 to 2010, the annual autopsy rate 
exceeded 30% and in 2015, it was 21%.334 In comparison, the concurrent autopsy 
rates were < 20% in other European Union states.334 The registry search was based 
on selected ICD-10 codes as well as specific keywords in the text body of the death 
certificate. Some patients may have been missed by this search protocol. This may 
be especially true for GCM, as it does not have a specific ICD-10 code. Finally, 
we had to reject a few cases from the cause-of-death registry where histological 
material could not be collected for evaluation.
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6.1.2 Data collection and analysis
Most of the data presented here was collected retrospectively from available medical 
documents. The histologic material obtained from autopsy-diagnosed cases, and 
from each GCM case, were, however, re-reviewed for the present work, as were 
the CMRI images in Study I. Regarding the cases of CS from the MIDFIN registry, 
histology was not consistently re-evaluated, but diagnoses made by pathologists 
in the attending hospitals were relied upon. The CMRI protocols and techniques 
evolved substantially during the 10-year period covered by Study I. CMRI was 
utilized less often in diagnostics of unknown cardiomyopathies at the beginning 
of this period, thus reducing the number of study subjects. In the present study, 
cardiac death was defined as SCD if prodromal symptoms occurred within 24 
hours of death. It was felt that adhering to the strict one-hour definition, commonly 
used in epidemiological studies, would have been inappropriate for the purposes 
of this work. Only “hard” endpoints such as fatalities, cardiac transplantations, 
and life-threatening VAs were collected. Despite the retrospective study design, 
these endpoints can usually be precisely defined from hospital charts. 
From a statistical point of view, the numbers of cases and endpoint events 
remain rather small. In several cases, some important laboratory or imaging data 
could not be obtained, further limiting the statistical power of our analysis. Due to 
the retrospective nature of our studies, only observational remarks can be made 
on the effects of immunosuppressive and other therapies in CS or GCM.
6.2 Comparison with previous data
6.2.1 Differential diagnostics of cardiac sarcoidosis and  
giant cell myocarditis
Our audit of all GCM cases in the registries exposed major diagnostic problems as 
more than half of the GCM diagnoses had to be converted to CS. One of the main 
reasons was that, in many forensic autopsies, cardiac or extracardiac granulomas 
had in fact been recognized and reported but the diagnosis was still set as GCM. In 
other cases, myocardial granulomas had simply escaped detection on microscopy. 
In postmortem studies in particular, tissue autolysis can impair the quality of 
histological material and hamper the detection of granulomas. During the original 
histological review for studies II and III, only myocardial specimens were analyzed, 
and only basic tissue stains (HE and Masson’s trichrome) were used. We found that 
previously missed granulomas could be discerned using immunohistochemical 
staining (see Figure 11). In a few cases, diagnostic reclassification was based on 
detecting sarcoid granulomas in either extracardiac organs or in a cardiac explant 
examined de novo. Finally, our decision to consider even immature granulomas 
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diagnostic of CS and exclusive of GCM had a major impact and needs emphasis 
here. It is of note that in the original works (studies II, III and Kandolin et al.6), 
only unequivocal fully-formed myocardial granulomas were considered diagnostic 
of CS.  
There is no unanimity among experts on whether granulomas can be seen in 
GCM. Moreover, it remains unsettled whether CS and GCM are truly different 
entities or if they represent a severity spectrum of one disease. Historically, since 
the first reported case of GCM in 1905,109 GCM and CS have usually been conflated 
when authors described cases of myocarditis associated with giant cells with or 
without granulomas and varying degrees of myocardial damage. In the 1950s, 
Tesluk et al. made a distinction between idiopathic GCM and granulomatous 
myocarditis (the common term in that era, describing what is now recognized as CS) 
by suggesting that GCM is characterized by a lack of myocardial granulomas and 
the presence of a diffuse inflammatory infiltrate and multinucleated giant cells.335 
Later in 1975, Davies et al. further promoted the differentiation between these 
entities by describing GCM cases with serpiginous areas of myocardial necrosis 
associated with giant cells and florid histiocytic and eosinophilic infiltrates.68 They 
concluded that CS was easily differentiated from this form of myocarditis by its 
easily recognizable granulomas. In another study by Litovsky et al., GCM cases 
showed extensive infiltrates of eosinophilia, myocytic destruction, lymphocytes of 
the CD8-type and an absence of granulomas.35 In contrast, myocardial granulomas 
were seen in all CS cases and the lymphocytes were predominately of the CD4 
type. Also, necrosis and eosinophilia were absent. Macrophagic giant cells were 
seen in CS cases and myogenic giant cells in the GCM cases.35 The complete 
absence of myocardial granulomas was the key differentiating histopathological 
characteristic in all these studies, as it was in our work, and the landmark report 
of the Multicenter GCM Study Group3 also adhered to this diagnostic fundament. 
Despite this, the very same group later modified their criteria for GCM allowing the 
presence of granulomas if the extent of myocardial necrosis was “out of proportion” 
to the amount of granulomas.4 The group concluded that granulomas and fibrotic 
changes are more frequent in CS, whereas areas of necrosis, foci of lymphocytic 
myocarditis, and eosinophilia are greater in GCM. There are reports suggesting 
that, in GCM, granulomas may also be found in extracardiac organs,3,35,68,257,335 
clouding the distinction even more. 
The results of our re-evaluation were highly dependent on the criteria used 
for GCM exclusion. Had we adhered to the definition by Okura et al.,4 where 
granulomas were not absolutely exclusive of GCM, the results would probably 
have been different. In our work, granulomas of any stage, in or outside the heart, 
excluded the diagnosis of GCM. Several aspects of both current and previous 
data call into question the concept of CS and GCM as fully separate entities. 
First and foremost, a T-cell mediated inflammatory process seems to be a key 
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pathogenetic factor in both diseases.33,35,37,54,56 Co-existing autoimmune disorders 
are equally common in sarcoidosis49–51,52,53 and GCM.3 Thymic tumors have been 
associated with GCM61–66 but are seen in sarcoidosis as well.53,336,337 Finally, there 
are impressive case reports of patients with lung or other organ sarcoidosis having 
myocardial histology of GCM.258,259,338 
CS and GCM resemble each other from a clinical perspective as well. Their 
spectra of cardiac manifestations are highly overlapping (Figure 2). Some 
differences in the presenting manifestation exist, however, with HF being the 
most common in GCM3,4,7 and AVB in CS.4,7,9 A fulminant manifestation with 
rapid progression is characteristic of GCM,3–5,7,251 whereas a prolonged disease 
course is more typical of CS.4,7 Still, severe forms of CS with rapid deterioration 
are reported170–172 and, conversely, GCM can present with a protracted clinical 
course.13,169 In summary, according to our experience and the available data, 
CS and GCM seem to be either two closely related T-cell mediated myocardites 
or simply represent different stages or severities of one and the same disease 
mechanism. In the single-disease hypothesis, GCM would represent an aggressive 
type of CS confined to the heart. Admittedly, these considerations remain mainly 
speculative pending more definitive research insight into the pathogenesis of these 
conditions. 
Finally, some methodological aspects of our histopathological analysis deserve 
a mention. The re-evaluation was made by two experienced cardiac pathologists 
whose consensus was required for each histological diagnosis. In conducting the 
review of histology, the pathologists were not fully blinded to the clinical data. 
The assessment of the extent of myocardial necrosis, fibrosis and eosinophilia was 
based on a visual estimation on an arbitrary four-point scale. Though subjective 




Regarding the epidemiology of CS, this study is a continuation of the recent 
thesis by Riina Kandolin.115 In her work, a significant increase was found in the 
detection rate of CS in Finland from the late 1980s until 2011. The current work 
updates the figures for CS diagnosed during life until the end of 2015. A significant 
addition, however, is the inclusion of cases detected from the national cause-of-
death registry (n=61) from a parallel period. These cases represent CS that was 
either asymptomatic during life or, if symptomatic, escaped correct diagnosis 
until autopsy. Some data from outside Finland also suggests that the detection 
rate of CS may be increasing. The number of CS-related hospitalizations and 
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transplantations in the US have substantially increased since the turn of the 
millennium.106,340,341 Improved diagnostics, especially advanced cardiac imaging 
might, at least in part, explain the increased detection of CS. According to several 
CMRI studies listed in Table 3, cardiac involvement in sarcoidosis is present in 20–
45% of cases.28,78,89,93–102 Another possibility is that the true incidence of sarcoidosis 
(and CS) is increasing. However, a Swedish registry-based study did not indicate 
any change in the number of incident cases of sarcoidosis over a 10-year period up 
to 2012. In contrast, another recent study, exploring a global database,342 reported 
that the age-standardized incidence rate of sarcoidosis showed an increasing trend 
from 1990 to 2017.343 
As mentioned earlier, most of the CS patients included here sought medical 
care for manifest and serious cardiac signs and symptoms. The epidemiological 
figures reported here do not cover asymptomatic but detectable CS as detailed 
cardiac screening of patients with systemic sarcoidosis was not common practice 
in the era our work represents. 
6.2.2.2 Giant cell myocarditis
GCM is an extremely rare disease. We detected a total of 29 GCM cases over a 
25-year period in Finland. While still few, 29 cases in a population of ≈ 5,500,000 
is a conspicuously high number compared to the figures of the Multicenter GCM 
Study Group3 for their immensely larger background population. Of note, their 
landmark paper was based on 63 patients detected from 49 medical centers 
representing 16 countries worldwide.3 Caforio et al. reported that, in a 13-year 
time period, five cases of GCM were identified amongst cases with suspected 
myocarditis referred to a tertiary center.113 Another report identified 10 GCM 
cases from 4738 consecutive patients undergoing EMB in a nine-year period for 
suspected myocarditis or DCM.111 A Finnish autopsy study by Kytö et al. found 
GCM in 5.6% of 142 patients with myocarditis registered as their cause of death, 
from 1970 to 1998.114
6.2.3 Patient characteristics and clinical manifestations
6.2.3.1 Cardiac sarcoidosis
Our series of 351 CS patients showed a clear female predominance (72%). Previous 
studies have reported both male4,108 and female8,10predominance in CS. The average 
age at symptom onset of 52±12 years is comparable to earlier reports.4,8,10,108 The 
spectrum of different presenting manifestations was also mainly in line with 
previous data.4,8,10,108 It has been recognized by our group and others that CS is a 
frequent cause of seemingly idiopathic AVB in young to middle-aged people.121,122 
As in the earlier MIDFIN registry based study,115 high-grade AVB was also the most 
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common main presenting manifestation in this study, being present in almost half 
of the patients at presentation. 
A life-threatening VA, or even SCD from VF, is not rare as the first sign of 
CS.4,8,108 In the present work, combining data from clinical and cause-of-death 
registries, 14% of all 351 patients had SCD as first manifestation of CS and another 
14% presented with sustained VT. In two earlier autopsy studies, SCD was the 
first sign of CS in 11–17% of all cases undergoing postmortem examination.14,15
6.2.3.2 Giant cell myocarditis
With a mean age of 57±13, our patients were older than the patients from the 
Multicenter GCM Study Group reports3,4 where the mean age was 42.5±13.2 in the 
full series.4 In the series of GCM patients surviving > 1 year by Maleszevski et al., a 
more comparable age distribution, with a mean age at diagnosis of 54.6±14.1 years, 
was reported.13 Like in CS, our GCM population showed a female predominance 
(69%). Previous studies have reported varying sex distributions with both male 
and female predominance in GCM.3–5,13,258 Concomitant autoimmune disorders 
were present in 14% of cases which is comparable to earlier data.3  
HF with depressed LV function was the most common main presenting 
manifestation of GCM in this series, being found in almost half of the cases. HF was 
also the most common first disease manifestation in the studies by the Multicenter 
GCM Study Group3,4 and by Maleszevski et al.,13 being present in 58–75% of cases. 
An arrhythmic event, sustained VT or SCD, was the first manifestation in one 
quarter of the patients. This is comparable with the Multicenter GCM Study Group 
report, where VT was the main presenting manifestation in 29% and VF in 3% of 
patients.4 High-grade AVB was found at presentation in 21% of our patients, being 
more common here than in the earlier study populations.3,4
6.2.4 Sudden cardiac death as the mode of death in cardiac sarcoidosis
It is well established that CS predicts a high risk of VAs. The incidence of significant 
VAs in known or suspected CS varies significantly between studies, with reported 
rates ranging from 7 to 60% (Tables 8 and 9). Still, no studies have systematically 
analyzed the frequency of SCD in fatalities from CS. A novel finding of this study 
was that SCD was the mechanism of death in as many as four out of five fatalities 
in a nationwide CS population. It should be noted that significant CAD was present 
at autopsy in six out of the 67 SCD fatalities and its contribution to the fatal event 
in these cases cannot be decisively determined. An outstanding and provocative 
observation was that, even after the exclusion of cases with concomitant severe 
CAD, SCD from previously undiagnosed CS accounted for 64% of all deaths. In 
over half of these cases, CS had apparently been clinically silent before the fatal 
event. It is noteworthy, however, that due to the inclusion of autopsy-diagnosed 
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cases, reverse survivorship bias may have increased the importance of the role 
of SCD in the present study.  
6.2.5 Incidence of life-threatening ventricular arrhythmias in giant cell 
myocarditis
Prior to this work, no studies have systematically reported the incidence of life-
threatening VAs in GCM. In this study, SCD was the mode of death in almost 
half of the fatalities, outnumbering both HF-related and post-transplant deaths 
(27% each). The cumulative incidence of life-threatening VAs rose steeply during 
the first 12 months after presentation, but very few arrhythmic events were seen 
thereafter (Figure 17B). It is noteworthy that, as cardiac transplantation and death 
from HF were considered competing events, few patients remained “at risk” after 
the first year (Figure 17B). The overall cumulative incidence of SCD at one year 
from symptom onset in this work was 41%. The corresponding figure for any life-
threatening VA was 52%. These figures are comparable with earlier reports3,4 and 
suggest a very high risk of life-threatening VAs in GCM 
6.2.6 Survival 
6.2.6.1 Cardiac sarcoidosis
Here, the five-year overall survival figures for all CS patients and for patients 
presenting with lifetime symptoms were 85 and 93%, respectively. These figures 
indicate better prognosis than what the studies prior to the turn of the millennium 
had suggested. In a British study of 250 CS patients from 1986, only 40% were alive 
five years after symptom onset.161 In another study of 95 Japanese CS patients,8 
the overall survival after five years was 60% and finally, Okura et al.4 reported a 
transplant-free survival rate of 60.5% at five years in CS patients collected from 
various centers in the US and Japan. More in line with the present results is a 
recent study reporting a five-year overall survival of 95.5% in 73 CS patients, of 
whom almost all were given immunomodulatory therapy and more than half 
received an ICD.108
Improved diagnostics and heightened suspicion of CS in the current era may 
have resulted in earlier diagnosis and detection of more benign forms of CS. 
Autopsy studies such as the widely-cited work of Roberts et al.,14 where only 27% 
of patients were alive at 12 months after onset of symptoms, are obviously biased 
towards very severe forms of CS. ICD implantation is probably the most important 
single intervention with a potential to reduce CS related deaths. In this study, 54% 
patients had an ICD while the respective figures were much lower in reports from 
the early 2000s.4,271
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6.2.6.2 Giant cell myocarditis
GCM is commonly depicted as an aggressive disease that very often necessitates 
cardiac transplantation. The overall survival of our patients presenting with lifetime 
symptoms was 67% at five years. Survival without cardiac transplantation at five 
years was 26%. The survival rates reported here are better than those reported 
by the Multicenter GCM Study Group showing a five-year transplantation-free 
survival of only 10%.4 The corresponding figure for their patients diagnosed by 
EMB was 21.9%.4 
6.2.7 Predictors of outcome 
6.2.7.1 Cardiac magnetic resonance imaging as a predictor for adverse 
events in cardiac sarcoidosis
We studied the prognostic role of CMRI in a group of 59 patients with myocardial 
biopsy confirmation of CS in more than half of the cases. In line with previous 
and later data,28,30,318,319 the amount of LGE on CMRI was predictive of the study 
endpoints, mainly consisting of life-threatening VAs. Other findings associated 
with worse outcome were impaired RVEF and scar-like thinning of the basal 
septum, both of which have been shown to associate with higher risk in other 
studies as well.28,212,310,317 Interestingly, LVEF was not associated with outcome 
events, highlighting the need for more accurate signals of high risk in CS than 
depressed LV function.
When mixed sarcoidosis populations, with or without cardiac symptoms, are 
screened for cardiac involvement, the mere presence of abnormal LGE associates 
with higher risk.28,93,94,96,100,212,318–320 The likely explanation is that the presence 
of LGE on CMRI, a diagnostic criterion for CS,80,83,84 identifies from such study 
populations individuals with cardiac involvement. In addition to the present study, 
only three other works have focused on the predictive role of CMRI in confirmed 
CS. Ours is, however, hitherto the only CMRI study where CS was diagnosed by 
the international HRS/WASOG criteria.83,84 The previous studies30,307,316 used the 
JMHW criteria,81,82 which are known for their issues of inferior sensitivity and 
specificity (see also section 2.6.1). 
6.2.7.2 Prognostic factors in giant cell myocarditis
With no comparable earlier data, a novel aspect of this work was the analysis 
of outcome predictors in GCM. Markers of severe inflammation and cardiac 
dysfunction were found to predict transplant-free survival, while the extent of 
myocardial fibrosis appeared as a particular predictor of SCD and life-threatening 
VAs. As myocardial fibrosis is a key pathophysiological factor contributing to VAs, 
it was not surprising that extensive fibrosis correlated with the occurrence of VAs. 
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Interestingly, LVEF at baseline did not stand out as an independent prognostic 
factor. Yet, as the numbers of patients and events were limited, these results should 
be interpreted cautiously. 
6.2.8 Comparison of cardiac sarcoidosis mimicking giant cell 
myocarditis vs. true giant cell myocarditis
As more than half of the cases originally diagnosed as GCM were ultimately 
deemed as CS, in many cases based on an evolution of previously set histological 
criteria,3,4,6,35,68,257 we were interested to find out whether these groups differed in 
terms of clinical characteristics and survival. The data shows that “true” GCM 
patients were older, presented more often with HF, had higher cardiac troponins 
and NT-proBNP on admission, and poorer long-term survival. These differences, 
and the observation that five-year survival in the group of CS mistaken for GCM 
was only 46%, imply that the latter cases most likely represented advanced and/or 
aggressive forms of CS. Importantly, even after adjusting for possible confounders, 
the histological diagnosis of CS was an independent predictor of a better outcome. 
It is of note that, for the patients initially diagnosed with GCM, biomarkers of 
cardiac injury and dysfunction and at least moderate myocardial necrosis or 
fibrosis retained their prognostic value for transplant-free survival irrespective 
of the final diagnosis (Study IIb). 
Moderate-to-severe fibrosis likewise remained an independent predictor of 
life-threatening VAs (Study IIIb). An interesting finding was that the cumulative 
incidence of SCD did not differ between “true” GCM and CS mistaken for GCM 
(Figure 18B). Since the cohorts in Study V were rather small it remains uncertain 
whether CS and GCM truly differ in terms of VA risk. As Figures 17B and 18B 
show, however, the overall absolute risk here was undisputedly significant in both.
6.3 Clinical implications and considerations for  
future research
The findings of this work underline the fact that, in clinical practice, life-threatening 
VAs probably constitute the most significant risk of poor outcomes in CS and GCM. 
In many cases, the cornerstone of care is the recognition of these potentially 
fatal myocardial diseases as the cause for sometimes unspecific cardiac signs 
and symptoms. In this study, 24 CS and three GCM patients, escaping a lifetime 
diagnosis, had cardiac manifestations that, in retrospect, are typical of these 
diseases. The present findings further underline the importance of considering the 
possibility of CS (or GCM) in all young or middle-aged patients with an apparently 
idiopathic high-grade AVB. The results of this work (Study I) and the findings of 
several other authors28,30,318,319 also suggest that the quantification of LGE might 
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help clinicians better stratify the risk of CS. Here, the risk was highest in patients 
with LGE > 22%, using the full-width at half-maximum method (Figures 10 and 
16). The measurement of the extent of LGE is sensitive to the method used,333 and 
some other threshold could also be appropriate. Also, the risk most probably is 
not dichotomic but rather increases with increasing amounts of LGE. Overall, our 
results suggest that the threshold for early ICD implantation should be kept low in 
CS and GCM. Although extensive fibrosis on EMB and high cTnT/I at presentation 
may be seen in GCM patients at the highest risk of VA/SCD, early ICD implantation 
is probably still warranted in all patients except those with a fulminant disease 
course where early listing for transplantation is required.
This study shows that the histopathological evaluation of inflammatory 
cardiomyopathy is demanding and requires a high level of expertise and 
experience. Immunohistochemistry may be helpful in the diagnosis and detection 
of immature myocardial granulomas. To differentiate between CS and GCM, every 
effort should be made not to miss cardiac or extracardiac granulomas. CT findings 
compatible with lung sarcoidosis and the identification of “hot” extracardiac lymph 
nodes or other abnormal 18F-FDG organ accumulation on PET should favor the 
diagnosis of CS. A novel finding of this work was that findings on EMB may have 
prognostic as well as diagnostic significance. Still, the clinician should probably 
tailor immunosuppressive therapy to the patient’s clinical status and the severity 
of myocardial injury and dysfunction rather than on histologic findings in a 
small sample of the myocardium. Lastly, for CS and GCM, the analysis of the 
cause-of-death registry showed that relying only on the ICD-10 codes and/or 
initial diagnosis, without further re-evaluation, may give false epidemiological 
information.
Regarding future research needs, more CMRI studies focusing on confirmed 
cases of CS are necessary to expand knowledge of the prognostic role of CMRI. 
In addition to the presence and extent of LGE, other characteristics like its 
heterogeneity should be focused on in future research. Cardiac imaging studies in 
GCM are highly anticipated, as current knowledge is based only on case reports. It 
is difficult to identify, and impossible to prove, the benefits of immunosuppression 
in either CS or GCM from retrospective observational studies or even from 
prospective registries. Randomized and controlled trials are needed and are long 
overdue. As CS and GCM are very rare diseases, such studies are not possible 
without research collaboration between institutions, hopefully internationally. In 
addition to clinical studies, basic and translational research is needed to better 
understand the pathogenesis of CS and GCM and to identify molecular targets for 
diagnosis and treatment. DNA analyses of large CS populations as well as more 
focused myocardial gene expression analyses and RNA profiling might be able to 
contribute in this way. Basic research could also help ultimately settle the issue 
of whether CS and GCM are different disease entities or parts of a continuum in 
one and the same inflammatory cardiomyopathy.  
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7 CONCLUSIONS
1. CS and GCM resemble each other both clinically and histopathologically. 
Their differentiation on biopsies is sensitive to the microscopic criteria used. CS 
can be mistaken for GCM if myocardial or extracardiac granulomas are missed 
or detected but are still perceived to represent GCM. In the present study, CS 
mistaken for GCM had a better outcome than “true” GCM. 
2. The detection rates of both CS and GCM are increasing. The most common 
clinical presentations are high-degree AVB in CS and symptomatic LV dysfunction 
in GCM. CS can present during life and escape diagnostic work-up until autopsy 
due to SCD. 
3. In both CS and GCM, an unexpected SCD can be the first and only disease 
manifestation. Its frequency as a form of presentation was 14% in both cohorts 
of the present series. SCD dominates the spectrum of fatalities in these diseases. 
Here, it was the mode of death in 80% of fatalities from CS and in 45% of fatalities 
from GCM.  
4. Although survival appears improved in CS, mortality is still worrying given 
that the patients are typically working-age individuals. The 10-year survival rate 
in patients diagnosed during life was 87%. 
5. CMRI provides useful information about predictors of outcomes in CS. In the 
present work, survival free of cardiac transplantation and life-threatening VAs 
was worse in patients with a higher extent of LGE, lower RVEF, and thinning of 
the basal LV septum. 
6. The prognosis of GCM, a disease once considered inevitably deadly without 
transplantation, appears more favorable today. Still, the transplant-free five-year 
survival was no better than 26%, with the overall five-year survival being 67%. 
These figures are based on more than two decades of experience with GCM in 
Finland. 
7. The present work shows that GCM has a more outstanding arrhythmogenic 
profile than previously considered. The incidence of life-threatening VAs was 
highest during the early months with the cumulative incidence of SCD or any 
life-threatening VA amounting to 52% by the end of the first year from disease 
onset. The risk of SCD was associated with at least moderate fibrosis on myocardial 
biopsy and higher circulating cTnT at presentation. 
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